Preventive potential of N-acetylcysteine in oxidative stress-related complications of prematurity by Ahola, Terhi
PREVENTIVE POTENTIAL OF N-ACETYLCYSTEINE IN 
OXIDATIVE STRESS-RELATED COMPLICATIONS 
OF PREMATURITY
Terhi Ahola
Paediatric Graduate School
Hospital for Children and Adolescents
University of Helsinki
Helsinki, Finland
Academic dissertation
To be publicly discussed with the permission of the Medical Faculty of the University of
Helsinki, in the Niilo Hallman Auditorium of the Hospital for Children and Adolescents,
on 28 May 2004, at 12 noon.
HELSINKI 2004
2Supervised by:
Professor Vineta Fellman 
Department of Paediatrics 
Lund University
Lund, Sweden
and
Hospital for Children and Adolescents
University of Helsinki
Helsinki, Finland
Docent Risto Lapatto
Hospital for Children and Adolescents
University of Helsinki
Helsinki, Finland
Reviewed by:
Professor Mikko Hallman
University of Oulu
Oulu, Finland
Docent Kirsti Heinonen
University of Kuopio
Kuopio, Finland
Opponent:
Professor Pekka Kääpä
Research Centre of Applied and Preventive Cardiovascular Medicine
University of Turku
Turku, Finland
ISBN 952-91-7212-5 (printed version)
ISBN 952-10-1855-0 (PDF)
Yliopistopaino 
Helsinki 2004
To Ilpo, Ville, Saara and Laura
Table of Contents
4
CONTENTS
LIST OF ORIGINAL PUBLICATIONS  6
ABBREVIATIONS  7
ABSTRACT  9
REVIEW OF THE LITERATURE 11
     1.   Oxidative stress in newborn infants 11
Production and cellular effects of reactive oxygen species (ROS) 11
Markers of oxidative stress in clinical samples 13
     2.   Antioxidant defence mechanisms in preterm infants 15
Antioxidant enzymes 17
Glutathione 20
     3.   Clinical implications of oxidative stress in preterm infants 24
ROS-related diseases 24
Bronchopulmonary dysplasia (BPD) 27
The role of ROS in the pathophysiology of BPD 28
Pharmaceutical interventions to prevent BPD 31
     4.   N-acetylcysteine (NAC) 33
Pharmacokinetics of NAC 34
Experimental evidence supporting the use of NAC in lung injury 35
Clinical applications of NAC in lung injury 35
AIMS OF THE STUDY 37
SUBJECTS AND METHODS 38
     1.   Study designs 38
     2.   Study populations 38
     3.   Drug administration and patient care 40
     4.   Safety and monitoring 41
     5.   Clinical data, outcome measures and follow-up 42
     6.   Biochemical analyses 42
Blood sampling 42
Plasma and erythrocyte thiols 44
Free 8-isoprostane 44
Ascorbyl radical 45
Erythrocyte glutathione cycle enzymes 45
     7.   Statistics 45
     8.   Ethical considerations 46
Table of Contents
5
RESULTS 48
     1.   Pharmacokinetics of NAC in preterm infants (I) 48
2. Effect of NAC in preventing BPD and other complications of 
      prematurity (II) 48
3. Plasma free 8-isoprostane and ascorbyl radical as markers of oxidative 
      stress (III) 51
4. Thiol metabolism and erythrocyte glutathione cycle enzymes in 
      preterm infants not receiving NAC (IV) 52
DISCUSSION 54
     1.   Methodological aspects 54
     2.   NAC in preventing complications of prematurity 55
     3.   Markers of oxidative stress 58
     4.   Thiol metabolism and erythrocyte glutathione cycle enzymes 60
     5.   Future prospects 61
CONCLUSIONS 62
ACKNOWLEDGEMENTS 63
REFERENCES 65
Original Publications
6
LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications referred to in the text by their
Roman numerals:
I Ahola T, Fellman V, Laaksonen R, Laitila J, Lapatto R, Neuvonen PJ and Raivio KO.
Pharmacokinetics of intravenous N-acetylcysteine in preterm newborn infants. Eur J
Clin Pharmacol 55:645-650, 1999.
II Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, Jonsbo F, Esberg
G, Stövring S, Kjartansson S, Stiris T, Lossius K, Virkola K and Fellman V. N-
acetylcysteine does not prevent bronchopulmonary dysplasia in extremely low birth
weight infants. J Pediatr 143:713-719, 2003.
III Ahola T, Fellman V, Kjellmer I, Raivio KO and Lapatto R. Plasma 8-isoprostane is
increased in preterm infants acquiring bronchopulmonary dysplasia or periventricular
leukomalacia. Pediatr Res 56(1):xxx-xxx, 2004. In press.
IV Ahola T, Levonen AL, Fellman V and Lapatto R. Thiol metabolism in preterm infants
during the first week of life. Scand J Clin Lab Inv. Submitted.
Abbreviations
7
ABBREVIATIONS
ARDS adult respiratory distress syndrome
BPD bronchopulmonary dysplasia
CL plasma clearance
CPAP continuous positive airway pressure
CuZnSOD copper zinc superoxide dismutase
EC-SOD extracellular superoxide dismutase
ELBWI extremely low birth weight infant
ELF epithelial lining fluid
ESR electron spin resonance
G6PDH glucose-6-phosphate dehydrogenase
GCL glutamate cysteine ligase
GC-MS gas chromatography-mass spectrometry
GPx glutathione peroxidase
GR glutathione reductase
GS glutathione synthetase
GSH reduced glutathione 
GSSG oxidized glutathione
GST glutathione-S-transferase
γ-GT γ-glutamyl transpeptidase
H2O2 hydrogen peroxide
HOCl hypochlorous acid 
HPLC high-performance liquid chromatography
8-isoprostane 8-epi-prostaglandin F2α
IVH intraventricular haemorrhage
MDA malondialdehyde
MnSOD manganese superoxide dismutase
mRNA messenger ribonucleic acid
NAC N-acetylcysteine
NAD(P) nicotinamide adenine dinucleotide (phosphate)
NEC necrotizing enterocolitis 
·NO nitric oxide
Abbreviations
8
O2·- superoxide radical
OH· hydroxyl radical
ONOO- peroxynitrite
PVL periventricular leukomalacia
RCT randomized clinical trial
RDS respiratory distress syndrome
ROP retinopathy of prematurity
ROS reactive oxygen species
RT-PCR reverse transcriptase-polymerase chain reaction
SOD superoxide dismutase
t1/2 half-life of elimination
Vd volume of distribution
VLBWI very low birth weight infant
XOR xanthine oxidoreductase
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ABSTRACT
Background: Oxygen therapy and inflammation are key factors in the pathogenesis of
bronchopulmonary dysplasia (BPD) and both increase the generation of reactive oxygen
species. The synthesis of glutathione, a major intracellular antioxidant, may not be adequate
in preterm neonates because of the low levels of cysteine available. N-acetylcysteine (NAC),
a free radical scavenger and a precursor for cysteine, has been suggested to increase
glutathione synthesis.
Aims: To determine whether NAC treatment improves the outcome of preterm infants by
preventing oxidative stress-related complications of prematurity, to identify a suitable risk
indicator of oxidative damage in extremely low birth weight infants (ELBWI) and to evaluate
thiol metabolism in preterm infants during the first week of life.
Design: We investigated the pharmacokinetics of NAC in preterm newborn infants and
applied the results in the NAC treatment protocol of a randomized, placebo-controlled,
double-blind multicentre trial. The primary outcome measures were death and prevalence of
BPD at the gestational age of 36 weeks. To identify a suitable risk indicator of oxidative
damage and to evaluate the effect of NAC infusion on this marker and on the risk of BPD or
death, we measured plasma 8-isoprostane and ascorbyl radical concentrations on days 3 and 7
in a subpopulation of infants participating in the multicentre trial. 
To further clarify the thiol metabolism during the first week of life, we studied plasma and
erythrocyte cysteine and glutathione in very low birth weight infants (VLBWI) and ELBWI,
as well as erythrocyte glutathione cycle enzymes in VLBWI.
Results: NAC is eliminated slowly in preterm infants, with a mean half-life of 11 hours,
which is clearly longer than that described for adults. The clearance of NAC correlates well
with weight and gestational age. In most infants, a steady-state concentration was reached
within 2-3 days at a constant infusion rate of NAC.
The randomized controlled trial, including 391 ELBWI, showed that intravenous NAC, at the
dosage used, did not prevent BPD or death in ELBWI. No adverse effects that could be
ascribed to NAC treatment were observed.
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Plasma 8-isoprostane concentrations during the first week of life were higher in the infants
who later developed BPD or died, and increased significantly more in infants who later
developed PVL. This marker of oxidative stress may be valuable for defining the risk group
for adverse outcome. NAC had no significant effect on plasma 8-isoprostane concentration.
The ascorbyl radical concentration on day 3 was significantly higher in those infants who
subsequently developed PVL. 
Plasma glutathione concentrations initially increased and plasma cysteine concentrations
initially decreased in VLBWI and ELBWI studied during the first week of life. Infants who
developed RDS already had lower glutathione concentrations during the first hours of life.
Furthermore, a correlation between intracellular cysteine and glutathione concentrations in
erythrocytes was present.
Conclusions: The pharmacokinetics of N-acetylcysteine in preterm infants is related to
weight and gestational age. The elimination of N-acetylcysteine is much slower in preterm
newborns than in adults. At 36 gestational weeks no beneficial effects of a 6-day course of
intravenous NAC, at the dosage used, were demonstrated on BPD. NAC treatment did not
have any impact on plasma free 8-isoprostane or ascorbyl radical. An association between
elevated plasma free 8-isoprostane, BPD and PVL, as well as between plasma ascorbyl radical
signal and PVL, was found. VLBWI and ELBWI have an initial increase in plasma
glutathione and an initial decrease in plasma cysteine concentration, in addition to a positive
correlation between erythrocyte cysteine and glutathione concentrations during the first week
of life.
Review of the Literature
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REVIEW OF THE LITERATURE
1.   Oxidative stress in newborn infants
Under physiological conditions, a balance exists between the amount of reactive oxygen
species (ROS) produced in normal cellular metabolism and the endogenous antioxidant
defence. An imbalance between the antioxidant capacity and the production of ROS leads to
oxidative stress, which is associated with the pathogenesis of several human diseases. 
The physiological circumstances during a normal birth can be classified as a hypoxia-
reoxygenation process. At birth, the newborn infant is exposed to considerably higher tissue
concentrations of oxygen than during foetal life. More than a fivefold increase in the partial
pressure of oxygen occurs in the arteries and airways, when the infant starts breathing. Even
during normal delivery oxygenation of the foetus decreases temporarily, and thus, the
postnatal increase in oxygenation is remarkable. Transition from relative hypoxia to
hyperoxia carries a risk of oxidative injury. However, healthy term infants seem to tolerate
this sudden hyperoxic challenge better than adults. In experimental studies, term newborn
animals of some species are capable of increasing their antioxidant enzyme activities during
hyperoxia, whereas adult animals have lost their capacity to respond to hyperoxic challenge
(Frank 1991). 
Preterm infants are not only exposed to relative hyperoxia at birth during the transition from
foetal life to air breathing but are also mechanically ventilated with oxygen supplementation
as part of the treatment of respiratory distress syndrome (RDS). In addition, preterm
newborns may experience reperfusion injury following insults of decreased tissue perfusion.
Infection is a major aetiological factor for preterm labour and delivery. In the newborn infant,
infection and inflammation cause activation of polymorphonuclear leucocytes, which in turn
can increase oxidative stress by generating ROS. The antioxidant defence mechanisms are not
fully developed in preterm infants, which further increases their vulnerability to oxidative
stress.
Production and cellular effects of reactive oxygen species (ROS)
Free oxygen radicals and other oxygen-related reactive compounds are collectively known as
ROS. Similarly, reactive nitrogen species (RNS) includes nitrogen-related reactive
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compounds (Table 1). A free radical can be defined as any molecule or atom capable of
independent existence that contains one or more unpaired electrons in the outer electron shell
(Halliwell and Gutteridge 1999). The presence of an unpaired electron sometimes makes the
free radical highly reactive, although the chemical reactivity varies widely between different
radicals. When a radical reacts with a non-radical, the latter usually becomes a radical, and
thus, a chain reaction is initiated. ROS can injure cell membranes by lipid peroxidation,
inactivate enzymes, degrade structural proteins, damage carbohydrates and injure DNA. They
are also involved in the apoptosis and necrosis of cells. Important free radicals in biological
systems include superoxide radical (O2·-), hydroxyl radical (OH·) and nitric oxide (·NO).
Hydrogen peroxide (H2O2), hypochlorous acid (HOCl), singlet oxygen and peroxynitrite
(ONOO-) are also included in the reactive oxygen or nitrogen species because they have the
potential to generate free radicals, although they are not free radicals by definition (Halliwell
and Gutteridge 1999). 
Table 1. Most important reactive oxygen and nitrogen species
Cells produce ROS, mainly O2·- and H2O2, even under normal aerobic metabolism. The most
important intracellular source of ROS is the electron transport chain in mitochondria, where
oxygen is reduced to water (Halliwell and Gutteridge 1999). About 1-2% of the oxygen
entering the respiratory chain accidentally leaks out as O2·-. This mitochondrial O2·- can
further dismutate to H2O2 (Fridovich and Freeman 1986) either spontaneously or by the
enzymatic action of superoxide dismutase (SOD). In the cytosol, ROS are formed both non-
enzymatically and by intracellular enzymes. Microsomal and nuclear membrane cytochrome
P450 enzymes can also produce O2·-. During inflammation O2·- production occurs by
activated polymorphonuclear leucocytes, mainly through membrane-associated NADPH
oxidase. Transition metals, such as iron and copper, donate or accept free electrons during
intracellular reactions, and catalyse free radical formation. In the presence of transition
metals, O2·- and H2O2 can form OH·, which is much more reactive than O2·- or H2O2. It reacts
with almost any biological molecule, and because of this high reactivity, OH· reacts at or
close to its site of formation. Transition metals also aggravate peroxidation of membrane
Reactive oxygen species (ROS) Reactive nitrogen species (RNS)
O2·- Superoxide ·NO nitric oxide
OH· Hydroxyl ·NO2 nitrogen dioxide
H2O2 Hydrogen peroxide N2O3 dinitrogen trioxide
HOCl Hypochlorous acid ONOO- peroxynitrite
RO· Alkoxyl RONOO alkyl peroxynitrite
ROO· Peroxyl
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lipids by catalysing the formation of peroxyl and alkoxyl radicals. ·NO is synthesized by nitric
oxide synthases in endothelial cells. It can react with O2·- to form the highly toxic ONOO-
(Halliwell and Gutteridge 1999). Xanthine oxidoreductase (XOR) does not produce detectable
amounts of ROS under normal conditions, but during reoxygenation after ischaemia, it can
produce O2·- and H2O2. However, the role of XOR in human pathology remains unclear.
Although ROS and RNS can cause damage to almost all components of the cell, they have
beneficial effects as well. The acute inflammatory response in activated leucocytes is targeted
to kill micro-organisms. ·NO is important in the regulation of smooth muscle tone and thus is
essential for the regulation of blood pressure (Moncada and Higgs 1993). Although ·NO can
mediate pro-oxidant effects, it also has antioxidant, chain-breaking properties (Rubbo et al.
1996). ROS also play an important role in signal transduction and gene expression (Sen and
Packer 1996), as well as in cell growth and differentiation (Burdon 1995, Jankov et al. 2001).
 
Markers of oxidative stress in clinical samples
Numerous methods exist for finding evidence of oxidative stress in clinical situations. One
approach is to measure the vulnerability to oxidative stress by analysing the amounts of
antioxidants, such as antioxidant enzymes and glutathione, or the change in antioxidant levels
in various situations. The direct detection of ROS is difficult and often impractical in the
measurement of oxidative stress in clinical samples. Electron spin resonance (ESR)
spectrometry with spin trapping is a technique in which the very short-lived free radicals are
allowed to react with a compound to produce a long-lived radical, which can be detected by
measuring the specific absorption spectrum (Halliwell and Gutteridge 1999). This method can
be used in biological models, but it is not suitable for measurements in live humans. A
modification of this technique takes advantage of the spontaneous occurrence of endogenous
substances with the same function, such as the semi-hydroascorbate radical. It is formed when
reduced ascorbate reacts with a free radical. The radical formed is relatively stable and
therefore can be measured in clinical samples (Bielski et al. 1975).
Because of their high reactivity, ROS have a short life span, and thus, the evidence of their
role in the pathogenesis of different diseases is mostly indirect. Indirect methods including
measurements of stable end-products from ROS interactions with cellular components are
used to assess the role of oxidative stress in disease pathogenesis. However, oxidation
products are also produced under normal metabolism. The normal baseline values of different
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oxidation products have seldom (if ever) been determined by all possible methods, and
therefore, it may be difficult to distinguish normal values from elevated values. There may
also be daily variation in the metabolism or production can be affected by other factors, such
as nutrition (Pitkänen et al. 1991). Proper sample handling is also critical. In addition,
production of oxidative metabolites can occur ex vivo, after sample collection. All of the
markers used do not measure the same series of events but can reflect the response of
different organs (Pryor and Godber 1991).
Among the most commonly used methods is the demonstration of end-products of lipid
peroxidation in clinical samples, including plasma, urine, tracheal aspirate, cerebrospinal
fluid, tissue or exhaled air. Lipid peroxidation is a process initiated by ROS. When OH· reacts
with (poly)unsaturated fatty acid chains of the membrane phospholipids, such as arachidonic
acid, water and carbon-centred radicals are formed. These can further react with oxygen to
create peroxyl radicals, which in turn can attack the adjacent side chain, thus enabling the
chain reaction of lipid peroxidation to continue. Transition metals can further accelerate the
process, and lead to formation of alkoxyl radicals. This chain reaction results in the
accumulation of lipid hydroperoxides, conjugated dienes and their degradation products,
aldehydes, gaseous alkanes and isoprostanes. These end-products of lipid peroxidation can
then be determined by various methods, among which mass spectrometry and antibody-based
methods are the most specific (Halliwell and Gutteridge 1999). 
Certain products of lipid peroxidation, such as 8-epi-prostaglandin F2α  (8-isoprostane), are
biologically active and may contribute to disease development (Vacchiano and Tempel 1994).
F2-isoprostanes are prostaglandin F2-like products formed in vivo mostly by non-enzymatic
peroxidation of membrane phospholipids by ROS. The most commonly determined
isoprostanes are derived from arachidonic acid and form the group of 8-isoprostanes.
Isoprostanes, stable compounds present in all normal biological fluids in detectable quantities,
have been shown to increase in animal models of oxidant injury (Roberts and Morrow 2000).
8-isoprostane is a potent vasoconstrictor of pulmonary vascular and airway smooth muscle.
Isoprostanes can be measured by high-performance liquid chromatography (HPLC) or gas
chromatography-mass spectrometry (GC-MS) methods or by radio- or enzyme immunoassays
(Janssen 2001).
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Another method to evaluate the impact of oxidative stress in different diseases is to measure
the oxidation of proteins, although oxidatively damaged proteins are often rapidly removed by
proteases and not accumulated as end-products of protein oxidation. ROS can modify the
amino acid residues in proteins, causing inactivation of enzymes and changes in their
structural conformations. The most commonly used method is determination of protein
carbonyls that are generated either by direct oxidation of proteins or by covalent binding of
aldehyde products of lipid peroxidation. These products can be measured after derivatization
with dinitrophenylhydrazine by HPLC with spectrophotometric detection, by Western blot
with antibodies raised against dinitrophenyl epitope (Levine et al. 1994) or by enzyme-linked
immunosorbent assay  (ELISA) (Buss et al. 1997). The reaction of ·NO and peroxynitrite with
amino acid tyrosine leads to formation of nitrotyrosine, which can be detected
immunologically or by HPLC or GC-MS techniques (Halliwell and Gutteridge 1999).
Chlorotyrosine is produced when HOCl, generated by the enzyme myeloperoxidase in
activated neutrophils, reacts with tyrosyl residues in proteins. It can be measured by GC-MS
or by immunological techniques (Winterbourn and Kettle 2000).
ROS can also produce irreversible modifications of DNA and smaller molecules, such as
urate. The end-products of these reactions can be measured when determining oxidative stress
in biological samples (Dizdaroglu et al. 2002).
2.   Antioxidant defence mechanisms in preterm infants
The antioxidant defence mechanism is made up of intracellular and extracellular components.
Their synergistic interaction is required for efficient protection against ROS. Antioxidants can
act by preventing the formation of ROS or by scavenging them. The repair mechanisms of the
damage caused by ROS are also important, but will not be discussed here. The antioxidant
enzymes and glutathione constitute the major part of the intracellular antioxidant defence. The
extracellular component contains preventive antioxidants, such as transferrin and
caeruloplasmin, and chain-breaking antioxidants, such as vitamins E and C, uric acid,
bilirubin and sulphydryl groups (Berger et al. 1998). It also contains antioxidant enzymes and
glutathione. 
Iron is normally sequestered by proteins so that it can be transported into cells. The
availability of free extracellular iron to react with O2·- and H2O2 is avoided through several
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mechanisms. Caeruloplasmin oxidizes free iron from ferrous to ferric ion, which is then
bound to transferrin, thus reducing the presence of non-protein-bound iron in extracellular
fluids and limiting the production of OH· (Gutteridge and Quinlan 1993). In infants who later
developed BPD, plasma transferrin concentration, but not caeruloplasmin, was lower at the
age of 10 days than in preterm infants without BPD (Moison et al. 1998). 
Vitamin E (α-tocopherol) is a major fat-soluble antioxidant in plasma and in membrane lipids
(Burton et al. 1983). Newborn infants are often deficient of vitamin E (van Zoeren-Grobben et
al. 1998), and their lipoproteins are therefore prone to peroxidation (Ogihara et al. 1991).
Vitamin E works in concert with vitamin C (ascorbate), which re-reduces the tocopheroxyl
radical, thereby permitting vitamin E to function again as a free radical chain-breaking
antioxidant (Buettner 1993). Vitamin C is usually considered an antioxidant, but at birth its
high levels could also act as a pro-oxidant (Lindeman et al. 1989). It can directly scavenge
O2·- or OH· by forming a semi-hydroascorbate radical that is subsequently reduced by reduced
glutathione (GSH) (McCay 1985, Carr and Frei 1999). It is also able to inhibit caeruloplasmin
activity in preterm infants, thus increasing the levels of free iron (Powers et al. 1995).
However, in preterm infants with high concentrations of plasma ascorbic acid, the plasma F2-
isoprostane and protein carbonyl concentrations were not different between infants with and
without bleomycin-detectable iron, suggesting that vitamin C does not act as a pro-oxidant in
preterm infants (Berger et al. 1997).
β-carotene, the most abundant carotenoid precursor of vitamin A in humans, is a powerful
scavenger of singlet oxygen and also inhibits lipid peroxidation in a low-oxygen environment
in vitro. However, it can act as an oxidant in some situations. Its role as an antioxidant in
humans remains to be clarified (Everett et al. 1996).
Uric acid, formed by the catabolism of purines, is present in all extracellular fluids, and it is a
major antioxidant in lung epithelial lining fluid (ELF). At birth, the plasma level of uric acid
can be higher than in adults. In healthy infants, levels increase during the first 24 hours but
rapidly decrease thereafter, while in infants with RDS levels remain higher during the first
three days of life (Raivio 1976) . Plasma allantoin is the oxidation product of uric acid. In
humans, it is not produced enzymatically, as in rodents, and thus, elevated concentrations are
always a sign of oxidative stress. In infants who later acquire BPD, plasma allantoin is
significantly elevated already on the first day of life (Moison et al. 1997a), and in tracheal
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aspirates of infants developing BPD, the allantoin/uric acid ratio is increased during the first
week of life (Ogihara et al. 1998). 
Albumin, as a transition metal binder, and bilirubin, as a chain-breaking antioxidant, can also
act as preventive antioxidants in plasma (Lindeman et al. 1995, Hammerman et al. 1998).
Although bilirubin is toxic to neurons at high concentrations, in a neuronal culture model, it
has proven to be neuroprotective against oxidative injury at nanomolar concentrations (Dore
et al. 1999). Plasma proteins, e.g. albumin, contain sulphydryl groups, which also contribute
to the antioxidant capacity of plasma. 
Maintaining the balance between ROS production and antioxidant defences in the lung may
be even more critical than in many other organs since the airways are exposed to relatively
higher levels of oxygen. The lung ELF contains a large number of antioxidants to prevent
airborne oxidant injury (Heffner and Repine 1989), such as glutathione, antioxidant enzymes;
SOD, catalase (CAT) and glutathione peroxidase (GPx), as well as other antioxidants present
in extracellular fluids (Cantin et al. 1987). 
Antioxidant enzymes
One of the most important cell self-protecting mechanisms against oxidative stress is the
antioxidant enzyme system, which includes SODs, CAT and the enzymes of the glutathione
redox cycle. In eucaryotic cells, three different types of SODs have been found. They are all
metalloproteins and catalyse the dismutation of O2·- to H2O2 and oxygen (McCord and
Fridovich 1969). The copper- and zinc-containing SOD (CuZnSOD) is present in virtually all
eucaryotes. It is mainly localized in the cytosol, although some activity has been detected in
peroxisomes and in the nucleus of human cells (Crapo et al. 1992). Manganese SOD
(MnSOD) is present in very high concentrations in the mitochondrial matrix (Fridovich and
Freeman 1986) and is considered a major protective molecule against O2·- leaking from the
respiratory chain. 
The extracellular form of SOD (EC-SOD) also contains copper and zinc at its active site. It is
the principal scavenger of O2·-  in the extracellular fluids and matrix (Oury et al. 1994). EC-
SOD is highly expressed in blood vessels, and it has been suggested to play an important role
in mediating intracellular signalling by ·NO, which is involved in smooth muscle relaxation,
neurotransmission and inflammation. When ·NO is released into the extracellular space of an
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environment with a high concentration of O2·-, it rapidly reacts to form ONOO- and then
nitrogen dioxide and OH·. EC-SOD can protect ·NO against O2·- -mediated inactivation and
also prevent the formation of more toxic radicals (Oury et al. 1996). Prenatal hypoxia has
been shown to decrease EC-SOD expression and to delay the secretion of active EC-SOD in
the airways in an animal model (Giles et al. 2002). In hyperoxia, the increased proteolytic
activity will result in depletion of EC-SOD from alveolar spaces, thus enhancing the oxidant-
antioxidant imbalance in the lung (Oury et al. 2002). 
CAT is an enzyme that decomposes H2O2, but not lipid hydroperoxides, to water and oxygen
(Chance et al. 1979). It is most effective in the presence of high H2O2 concentrations. In
humans, CAT is most abundant in the liver, where it is mainly located in peroxisomes
(Halliwell and Gutteridge 1999). Since H2O2 diffuses readily, CAT in erythrocytes can protect
other tissues against oxidative damage by scavenging H2O2  (Winterbourn and Stern 1987).
The glutathione redox cycle, including the enzymes GPx and glutathione reductase (GR), is
the main mechanism in scavenging lipid peroxides (Chance et al. 1979). GPx also
decomposes H2O2 and is considered more important than CAT in situations where only low
levels of H2O2 are produced (Fridovich and Freeman 1986).
The human lung has recently been shown to express other enzymes with H2O2-consuming
capacity, namely thioredoxin peroxidases, also known as peroxiredoxins (Kinnula et al.
2002). Thioredoxins are small cysteine-containing redox proteins that reduce oxidized
cysteine groups on proteins. The oxidized thioredoxin is then reduced back by thioredoxin
reductase in a NADPH-dependent reaction (Holmgren and Björnstedt 1995, Powis and
Montfort 2001). Animal studies suggest that thioredoxin modulates pulmonary inflammatory
responses and may prevent lung injury (Hoshino et al. 2003). Peroxiredoxins use thioredoxin
as the source of reducing equivalents for the reduction of  H2O2 (Rhee et al. 1999), whereas
glutaredoxins, another member of the thioredoxin superfamily, catalyse reductions of
disulphides in a coupled system with GSH, NADPH and GR (Fernandes and Holmgren
2004). The roles of peroxiredoxins and glutaredoxins in the antioxidant defence of the human
lung remain to be clarified.
The expression of antioxidant enzymes appears to be species-specific. In animal studies, the
concentration of such important antioxidant enzymes as SOD, CAT, and GPx is low in the
foetal lung but increases towards term (Frank and Sosenko 1987). Preterm delivery would
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thus expose the immature lung to elevated oxygen levels at a time when enzymatic defences
are not fully developed. However, studies on the ontogenesis of antioxidant enzymes in
humans have not been able to show such an induction in SOD and GPx in late gestation. The
mRNA levels of pulmonary MnSOD, CuZnSOD and CAT increase toward term and
adulthood in humans (Strange et al. 1988, McElroy et al. 1992, Asikainen et al. 1998), but the
activities of these enzymes, with the exception of CAT, have not been shown to increase
during ontogenesis (McElroy et al. 1992, Asikainen et al. 1998).
In some species, pre-exposure to hyperoxia or hypoxia causes an induction of antioxidant
enzymes, thus protecting the animal against later hyperoxic challenge (Kimball et al. 1976,
Frank et al. 1978, Frank 1982). Term newborn rats have also been shown to be more tolerant
to hyperoxia than adult rats because they have the capacity to increase their pulmonary SOD,
CAT and GPx levels (Frank et al. 1978, Yam et al. 1978). However, prematurely born
animals, at least rabbits and baboons, were unable to augment their antioxidant enzyme
activities when exposed to hyperoxia (Frank and Sosenko 1991, Morton et al. 1999). In the
baboon model, a decrease in CuZnSOD activity, with no change in CuZnSOD mRNA or
protein, and an increase in MnSOD mRNA and protein, but not activity, were seen in the
lungs of less premature animals. In the most premature animals, a decrease in CuZnSOD
activity and protein and an increase in CuZnSOD mRNA, were seen. No change in the lung
MnSOD activity after oxygen exposure was observed, and despite increased mRNA
expression, no MnSOD protein could be detected. These findings suggest that both post-
translational modifications and impaired translation are implicated in the failure to increase
antioxidant enzyme activities in hyperoxic challenge (Morton et al. 1999).  
Studies on the regulation of antioxidant enzyme activities in hyperoxia in the lungs of human
infants are scarce, being limited for ethical as well as practical reasons. In one study, neither
the expression of CuZnSOD or MnSOD, nor the activity of CuZnSOD in infants with RDS or
BPD differed from control infants (Strange et al. 1990). In another study, the expression of
MnSOD was not increased in type II pneumocytes of oxygen-treated infants with RDS or
BPD as compared with age-matched controls, suggesting that human infants are unable to
increase the amount of MnSOD protein in hyperoxia (Asikainen et al. 2001).
Although the activities of CuZnSOD and MnSOD in the lung do not increase towards term,
the activity of CuZnSOD in cord erythrocytes has been shown to be significantly lower in
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preterm than in term infants. The activity increased towards the expected date of delivery but
did not reach the same level as in infants born at term. This may render preterm infants even
more vulnerable to oxidative stress (Phylactos et al. 1995).
Glutathione 
The significance of different defence mechanisms varies depending on the type of oxidant and
cell. However, one of the most important intracellular antioxidant systems appears to be the
glutathione redox cycle. Glutathione (L-γ-glutamyl-L-cysteinylglycine) usually represents the
major intracellular non-protein thiol and is present in virtually all animal cells in relatively
high concentrations (0.1-10 mM) (Meister 1995). In the cell, almost 90% of glutathione is in
the cytosol, 10 % in the mitochondria, and less than 1% in the nucleus and endoplasmic
reticulum (Meister 1991). Glutathione exists in both reduced (GSH) and oxidized (GSSG)
forms, the former predominating (>99% under normal conditions) (Meister and Anderson
1983). 
Glutathione is synthesized in the cytosol by the sequential actions of the enzymes glutamate-
cysteine ligase (GCL, also known as γ-glutamylcysteine synthetase, γ-GCS) and glutathione
synthetase (GS) from cysteine, glutamate and glycine in the γ-glutamyl cycle (Meister and
Anderson 1983) (Figure 1). Both enzymes are exclusively cytosolic. The first step catalysed
by GCL is rate-limiting. GCL activity is regulated by negative feedback of GSH and by the
availability of cysteine (Deneke and Fanburg 1989). Oxidative stress has been shown to
enhance the synthesis of GSH through induction of GCL (Rahman and MacNee 1999). 
Studies on the ontogenesis of the enzymes important in glutathione synthesis in man have
shown that GCL activities in the liver  (Rollins et al. 1981, Levonen et al. 2000b), lung,
kidney (Levonen et al. 2000b) and erythrocytes (Lestas and Rodeck 1984) are similar in
foetuses, neonates and adults. In humans, the activity of GS in the foetal liver has been
reported to be in the same range as that in the adult liver (Rollins et al. 1981), but lower than
in foetal erythrocytes (Lestas and Rodeck 1984). Without separating the activity of each
enzyme, glutathione synthesis rate in leucocytes derived from tracheal aspirate and cord blood
has been shown to be higher in preterm infants than in term infants in post-operative state
(Lavoie and Chessex 1998). Interestingly, in human alveolar cells (A549), significant
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decreases in GSH concentrations and GCL activity were shown after a 24-hour exposure to
dexamethasone (Rahman et al. 1999).
Figure 1. γ-glutamyl cycle. cys, cysteine; glu, glutamate; gly, glycine; cys-gly, cysteinyl-glycine; γ-glu-cys, γ-
glutamyl-cysteine; DP, dipeptidase; GCL, glutamyl-cysteine ligase; GS, glutathione synthetase; γ-GT, γ-
glutamyl transpeptidase; cyclotransferase, γ-glutamyl cyclotransferase. See text for details.
Glutathione has a significant role as the reservoir and transport system of cysteine, the other
major thiol, i.e. a molecule with a sulphydryl (-SH) group, which is extremely prone to
oxidation in the extracellular milieu. Cysteine is required for the synthesis of GSH, proteins
and several other metabolites. Once formed in the γ-glutamyl cycle, intracellular GSH may be
released from the cell by a carrier-mediated transporter. A transmembrane protein, γ-
glutamyltransferase (γ-GT), then transfers the γ-glutamyl moiety to an amino acid, preferably
to cystine, thereby forming a γ-glutamylamino acid and cysteinylglycine, which may be split
to cysteine and glycine. Cysteine is readily taken up by most cells, and reused for the
synthesis of GSH. The γ-glutamylamino acid can also be transported back into the cell and
used for GSH synthesis, after the release of the amino acid and further conversion to
glutamate (Meister and Anderson 1983, Meister 1991). For most cells, this mechanism
provides a continuous source of cysteine (Lu 1999). The export of GSH also protects the cell
membrane against oxidative damage by maintaining thiol groups and other components of the
membrane, such as α-tocopherol, in reduced form. Moreover, it may provide reducing
compounds in the immediate vicinity of the cell membrane (Meister 1991). 
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In the liver, the synthesis of GSH is high and dependent on the availability of cysteine, either
dietary or synthesized in the liver from methionine through the transsulphuration pathway
(Reed and Orrenius 1977). Furthermore, liver epithelial cells are known to have a high
capacity for GSH efflux (Ookhtens and Kaplowitz 1998). Liver is thus a net synthesizer of
circulating GSH, which can be taken up by other organs. However, GSH does not enter the
cells as such, but the GSH exported from the liver is mainly degraded by γ-GT and
dipeptidase to its constituent amino acids and the main thiol in plasma, cysteine, which can be
further reused by extrahepatic cells for the synthesis of GSH. Cysteine is transported into cells
by the Na+-dependent pathways ASC or A (Bannai 1984). Cystine, the oxidized disulphide of
cysteine, can also be used to increase the intracellular cysteine levels. The transport of cystine
into cells differs from that of cysteine. The Xc- system is independent of Na+ and is induced
by hyperoxia and various oxidants in the lung (Deneke and Fanburg 1989). In the cell, cystine
is rapidly reduced to cysteine. 
Although the ability of the cells of preterm infants to synthesize glutathione seems to be
adequate, the availability of cysteine, the rate-limiting substrate, may hinder GSH synthesis in
this patient group, which is often exposed to significant oxidant stress. In preterm infants, the
transsulphuration pathway from methionine to cysteine is impaired because of deficient
cystathionase activity in the liver; hence, cysteine is considered an essential amino acid for
these infants (Sturman et al. 1970, Gaull et al. 1972, Levonen et al. 2000a). Lower plasma
cysteine and higher cystathionine concentrations have been reported in preterm compared
with term infants (Viña et al. 1995). Studies on very low birth weight infants during the first
week of life, when they receive mostly parenteral nutrition, have shown that plasma cysteine
levels decrease more, relative to term reference values, than any other amino acid (van
Goudoever et al. 1995). Relative GSH deficiency has been documented in preterm infants,
and is dependent on the degree of immaturity (Jain et al. 1995). Controversially, total
glutathione (GSH+GSSG) in erythrocytes from cord blood has been reported to be higher in
preterm than in term infants. In addition, a rapid decline in erythrocyte glutathione content
both in preterm and term infants has been described (Jean-Baptiste and Rudolph 2003).
The glutathione redox cycle plays a major role in the reduction of intracellular
hydroperoxides. Glutathione peroxidases remove H2O2 and other peroxides. During this
enzymatic reduction of peroxides GPx oxidizes GSH to GSSG, which is then reduced back to
GSH by GR at the expense of NADPH. The NADPH required in this reaction is mainly
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provided by the oxidative pentose phosphate pathway, the first enzyme of which is glucose-6-
phosphate dehydrogenase (G6PDH) (Chance et al. 1979) (Figure 2).
Figure 2. Glutathione redox cycle.
In addition, glutathione-S-transferases (GSTs) catalyse the conjugation of glutathione with
lipid hydroperoxides and other lipid oxidation products, such as 4-hydroxy-2-nonenal, thereby
protecting against the deleterious effects of these potentially cytotoxic compounds. Severe
oxidative stress may lead to accumulation of GSSG in the cytosol if the capacity of GR is
exceeded. This may further lead to depletion of intracellular GSH because excess GSSG is
exported out of the cell to avoid a shift in cell the redox capacity (Lu 1999). Therefore, a
decrease in GSH or an increase in the GSSG/GSH ratio have been regarded as sensitive
indicators of oxidative stress. Low intracellular GSH in experimental situations will sensitize
cells to the cytotoxic action of ROS. The glutathione redox activity is highest in erythrocytes
and in the liver (Marklund et al. 1982). 
The enzymes of the glutathione redox cycle have been studied in erythrocytes of preterm
infants. In some studies, the activity of GPx has been shown to be lower in foetuses (Lestas
and Rodeck 1984) and preterm infants, than in term infants or adults (Gross et al. 1967,
Whaun and Oski 1970, Ripalda et al. 1989, Miyazono et al. 1999), but contradictory results
have also been reported (Varga et al. 1985, Candlish et al. 1995). The activities of GR and
G6PD in foetuses (Lestas and Rodeck 1984) and preterm infants have been observed to be
higher than in term infants and adults (Vetrella and Barthelmai 1971, Miyazono et al. 1999).
GST activity correlates negatively with gestational age (Ripalda et al. 1989, Neefjes et al.
1999).
In addition to the glutathione redox cycle, glutathione is important in many vital functions,
including detoxification of xenobiotics, maintenance of the intracellular redox balance and the
essential thiol status of proteins, and modulation of cell proliferation (Cotgreave and Gerdes
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1998, Lu 1999). It is implicated in immune modulation and inflammatory conditions.
Glutathione can also react non-enzymatically  with OH· and ONOO-  (Radi et al. 1991, Mayer
et al. 1995, Wink and Mitchell 1998). The latter reaction leads to the formation of
nithrosothiol (GSNO), which can decompose to ·NO, and thus, GSH can participate in
recycling ONOO-   to ·NO (Halliwell and Gutteridge 1999). Glutathione can also inhibit
radical production from the reaction of copper or iron with H2O2 thus protecting DNA from
oxidation (Hanna and Mason 1992, Spear and Aust 1995).
Glutathione has been reported to play a critical role in protection against oxidative injury in
the lung (Li et al. 1994, Li et al. 1996). The lung ELF contains high levels of glutathione,
more than 100-fold higher than in plasma (Cantin et al. 1987). Lung epithelial cells have high
levels of  γ-GT, and they utilize extracellular GSH from the ELF (Berggren et al. 1984). In
preterm infants, a negative arteriovenous gradient of GSH across the lung has been reported,
suggesting pulmonary uptake of GSH in the human lung (Smith et al. 1993). Plasma
concentrations of GSH in preterm infants treated with oxygen have been shown to be
significantly lower than in adults, whereas plasma concentrations of GSSG were significantly
higher, and inversely correlated with inspired oxygen tensions (Smith et al. 1993). Term
infants with persistent pulmonary hypertension, treated with mechanical ventilation and high
concentrations of oxygen due to acute pulmonary failure, as well as preterm infants with
RDS, had lower plasma concentrations of cysteine than term infants without respiratory
distress (White et al. 1994). In preterm infants with RDS, an increase in blood GSSG  and the
GSSG/GSH ratio, and a decrease in GSH in correlation with fractional inspired oxygen
concentration have been shown (Nemeth and Boda 1989). In the same study, the most preterm
infants had the highest GSSG levels. However, another study showed no difference in the
erythrocyte GSH/GSSG ratio in infants with or without RDS during the first two weeks of life
(van Zoeren-Grobben et al. 1997). 
3.   Clinical implications of oxidative stress in preterm infants
ROS-related diseases
The production of ROS is increased in several clinical situations, including hyperoxia,
inflammation and reperfusion of ischaemic organs (Freeman and Crapo 1981, Jamieson et al.
1986, Sussman and Bulkley 1990, Groneck et al. 1994). All of these are relevant in the
context of prematurity. There is increasing, although mostly indirect, evidence that ROS are
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implicated in the pathogenesis of disorders associated with prematurity. According to the
hypothesis of neonatal oxygen radical disease, BPD,  retinopathy of prematurity (ROP),
intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotizing
enterocolitis (NEC), and patent ductus arteriosus (PDA) all represent different manifestations
of the same disease caused by attacks of free radicals (Saugstad 1998). Urinary MDA
concentration has been shown to be higher in the most immature infants (Schlenzig et al.
1993). A correlation between lipid peroxidation products and the degree of immaturity has
also been demonstrated (Varsila et al. 1994, Inder et al. 1996). 
Neural tissue is rich in polyunsaturated fatty acids that are prone to lipid peroxidation. In the
premature infant, this tissue also contains an excess of free iron, which makes it even more
vulnerable to free radical reactions. The retina originates from the same embryonic tissue as
brain, and therefore, changes in the immature retina during the neonatal period might give
clues to the mechanisms of brain injury as well.
In the pathogenesis of ROP due to deficient autoregulation of the choroidal and retinal
circulation, the delivery of excess oxygen to the immature retina, rich in polyunsaturated fatty
acids, leads to generation of lipid peroxides, including vasoactive isoprostanes. This results in
vasoconstriction and endothelial cell degeneration, causing ischaemia and development of
vasoproliferative retinopathy of prematurity (Hardy et al. 2000, Hou et al. 2000). Erythrocytes
in preterm infants with active ROP have higher levels of GSSG, a higher GSSG/GSH ratio
and lower levels of GSH, than erythrocytes in infants without ROP (Papp et al. 1999). 
In the context of IVH, often associated with brain tissue injury, ROS produced during
ischaemia and reperfusion cause endothelial cell injury, resulting in capillary damage and
haemorrhage.  
PVL is associated with long-term adverse neurodevelopmental outcome of extremely low
birth weight infant (ELBWI). ROS production may occur by a variety of mechanisms in the
pathogenesis of PVL, including inflammation/infection and ischaemia-reperfusion (Volpe
2001). Ischaemia leads to energy failure in brain cells, resulting in loss of membrane potential
and influx of Na+, Ca++ and water, resulting in cell oedema. The increase in intracellular Ca++
leads to mitochondrial dysfunction, increased formation of ROS and activation of proteases,
lipases and endonucleases, which initiate processes leading to cell death. During ischaemia
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ATP is metabolized to hypoxanthine, which during reperfusion reacts with oxygen, producing
O2·- and H2O2, through the action of XOR. H2O2 is normally degraded to water and oxygen by
CAT and glutathione peroxidase. However, CAT activity is low in the oligodendrocytes of
preterm infants (Houdou et al. 1991). Although the XOR content of premature brain tissue is
low, XOR mRNA has been found with the reverse transcriptase-polymerase chain reaction
(RT-PCR) method in the developing brain (Saksela et al. 1998), possibly due to the presence
of XOR in arterial and capillary vascular endothelial cells. The intracellular rise in calcium
levels also leads to increased synthesis of ·NO, which, like free iron, can raise the toxicity of
O2·- by converting them to more potent radicals.
The early differentiating oligodendrocytes of the immature brain are extremely vulnerable to
free radical damage. The excess of free iron needed in the differentiation of oligodendrocytes
and in myelination or released from erythrocytes after intraventricular haemorrhage can
further increase the formation of ROS (Volpe 2001). 
Glutamate is an excitatory neurotransmitter that is released during ischaemia from presynaptic
vesicles. Glutamate-induced cell death has been shown to be related to glutathione depletion
caused by intracellular cystine depletion (Yonezawa et al. 1996). Ischaemia-reperfusion, as
well as infection, can induce an inflammatory response, with increased cytokine production
and activation of inflammatory cells (Fellman and Raivio 1997, Volpe 2001). Activated
neutrophils can further aggravate the oxidative damage by producing ROS. 
Elevated levels of 8-isoprostane in the cerebrospinal fluid have been demonstrated in preterm
infants with cystic PVL as compared with infants of the same gestational age with minor
white matter injury (Inder et al. 2002b). Moreover, elevated levels of non-protein-bound iron
in the CSF have been found in preterm infants with post-haemorrhagic ventricular dilatation
(Sävman et al. 2001). In a case report, elevated levels of protein carbonyls, 8-isoprostane,
chlorotyrosine/tyrosine ratio and MDA in the cerebrospinal fluid during the evolution of PVL
in a preterm infant with meningitis were shown (Inder et al. 2002a)
ROS produced by activated leucocytes and by intestinal epithelial XOR have been
hypothesized to be the final pathways for tissue injury in NEC (Hsueh et al. 2003). Both
ischaemia-reperfusion and inflammation seem to play a major role in the pathogenesis of
NEC. XOR activity is found in the human intestine throughout gestation and appears to
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decrease towards term (Vettenranta and Raivio 1990, Saksela et al. 1998). On the other hand,
endothelial ·NO is an important regulator of vascular perfusion. It helps to maintain the
integrity of the mucosal barrier, increases blood flow and inhibits leucocyte adhesion. ·NO is
synthesized from the amino acid L-arginine, which has been shown to reduce the incidence of
NEC in preterm infants (Amin et al. 2002).
Bronchopulmonary dysplasia (BPD)
BPD is one of the most important causes of long-term morbidity after preterm birth (Jobe and
Bancalari 2001). The definition of BPD has varied in the literature. The most widely used
definition has been the need for supplemental oxygen at the age of 28 days and typical
radiological changes. The need for oxygen therapy at the age of 36 gestational weeks has
during the last decade been the standard definition. A recent proposal by Jobe and Bancalari
(2001) is that BPD be categorized by the severity of the disease, and that a distinction be
made between infants born before and after 32 gestational weeks. 
The clinical presentation of BPD with inflammation, fibrosis, and smooth muscle hypertrophy
in the airways has changed since it was first described by Northway et al. (1967). The classic
BPD was more related to mechanical injury, high inspiratory pressure and direct oxygen
toxicity caused by the high levels of oxygen needed to treat infants with acute RDS. Due to
improved methods of intensive care, such as antenatal glucocorticoids, surfactant replacement
therapy (Hallman et al. 2001) and gentler ventilation techniques, large preterm infants seldom
develop BPD. These advances have made survival possible for more immature infants.
However, the incidence of BPD has not declined, but its clinical picture and pathologic
findings have changed. During the two-year period from 1996 to 1997 in Finland, 62% of
ELBWI either died (38%) or developed BPD (24%), yielding a 39% incidence of BPD for
survivors (Tommiska et al. 2001). BPD now occurs in VLBWI with minimal or no initial lung
disease with increasing oxygen and ventilatory needs during the first weeks of life (Rojas et
al. 1995). The major manifestation of the new BPD is an arrested alveolar and vascular
development of the lung (Husain et al. 1998, Jobe 1999). The lungs of infants dying of BPD
show less fibrosis, but there are fewer and larger alveoli. This indicates an interference with
septation despite the increase of elastic tissue in response to volutrauma (Thibeault et al.
2000). Immaturity, male sex, chorionamnionitis, sepsis, PDA and severe RDS are associated
with an increased risk of BPD (Rojas et al. 1995, Watterberg et al. 1996, Yoon et al. 1999,
Bancalari et al. 2003). A retrospective study on the risk factors for BPD development in
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VLBW infants showed that low birth weight and gestational age, male sex, packed red cell
infusion and long duration of ventilator treatment were correlated with increased risk for BPD
at the age of 28 postnatal days. Pre-eclampsia, low birth weight, rapid birth weight recovery,
packed red cell infusion, long duration of ventilator therapy, patent ductus arteriosus and
hyperoxia were associated with BPD beyond 36 gestational weeks (Korhonen et al. 1999).
While no specific evidence based treatment exists for BPD, symptomatic therapies, such as
supplemental oxygen, fluid restriction and systemic and inhaled steroids, are widely used.
Role of ROS in the pathophysiology of BPD
The pathogenesis of BPD is multifactorial, but among the key factors are oxygen therapy and
inflammation. Both are known to induce increased production of ROS and release of pro-
inflammatory cytokines, which are capable of damaging cells and tissues as well as
interfering with lung development. In the preterm infant, low levels of antioxidants,
antiproteases and anti-inflammatory cytokines can disturb the balance between inflammatory
and anti-inflammatory mechanisms, causing persistent inflammatory reaction and injury. 
The inflammatory response may be initiated by different insults, including pulmonary
barotrauma, oxygen toxicity, increased blood flow due to PDA and pulmonary and systemic
infections. The inflammation is characterized by accumulation of neutrophils and
macrophages in the lungs. Activated neutrophils can cause severe lung damage by release of
potent proteases, such as elastase and collagenase, as well as pro-inflammatory cytokines and
by production of ROS. Under normal circumstances, free elastase is rapidly inactivated by
α1-proteinase inhibitor (α1-PI), but ROS can cause inactivation of α1-PI, thus resulting in an
imbalance between elastase and α1-PI (Merritt et al. 1983). ROS can further increase the
toxicity of neutrophil elastase, leading to lipid peroxidation and membrane damage. The
cascade of events is complex; cytokines can further induce generation of ROS, or ROS can
lead to further release of cytokines. An increased production of inflammatory mediators has
been shown in infants acquiring BPD (Groneck et al. 1994). Lipid peroxidation caused by an
excess of ROS becomes autocatalytic, and finally leads to perturbation of cell membrane
function and cell death.
 
In non-phagocytic cells, probably most of the ROS production is derived from mitochondria,
and under hyperoxic conditions ROS production by lung cells is increased three- to fivefold in
vitro (Turrens et al. 1982).  Pulmonary vascular endothelial cells are especially vulnerable to
Review of the Literature
29
hyperoxia, which can lead to increased microvascular permeability, resulting in lung oedema
(Crapo 1986). This can deteriorate the ventilation/perfusion matching and increase the need
for oxygen, with even more severe cell damage ensuing. 
Another source of ROS is free iron-catalyzed production of OH·. Iron is important for normal
lung function, but an increased concentration  or aberrant regulation of iron metabolism or
deficient antioxidant protection is associated with lung diseases (Quinlan et al. 2002). Preterm
infants have free iron in the alveolar space (Gerber et al. 1999). Free iron enhances the
production of OH· and O2·-, which together with ·NO released from endothelial cells, can
form highly toxic ONOO-. ONOO- can induce surfactant dysfunction by lipid peroxidation
and damage to surfactant protein (Haddad et al. 1993, Moison et al. 1993).
The role of XOR in the production of ROS during ischaemia and reperfusion in the human
lung is unclear. Only low enzyme activity, and scarce amounts of XOR mRNA with a very
sensitive assay, RT-PCR, have been detected in the human lung (Saksela et al. 1998, Linder et
al. 1999). As in brain injury, XOR in lung endothelial cells may be important (Moriwaki et al.
1993). XOR has also been proposed to be released into the circulation from organs containing
high levels of XOR, such as the liver, and then bind to the endothelium, thus contributing to
the production of XOR in distant organs (Pesonen et al. 1998, Houston et al. 1999).
In animal models, hyperoxia may severely disrupt alveolar septation via the formation of ROS
(Thibeault et al. 1990, Coalson et al. 1995). In a neonatal mouse model, the effect of
hyperoxia on foetal mouse lung morphogenesis was reduced by antioxidants interfering with
O2·- and OH· formation (Wilborn et al. 1996).
Current data show that oxidative stress is involved in the development of BPD, although the
pathogenesis is not fully understood. Evidence for inflammation, increased oxidant
production and oxidant-induced macromolecular damage has been found in tracheal aspirates,
urine, exhaled air and plasma of infants acquiring BPD, albeit the results are somewhat
controversial. The early appearance of some of these markers suggest that pre- and perinatal
factors, such as inflammation (Yoon et al. 1999) and early resuscitation with high
concentrations of oxygen (Vento et al. 2003), may have an important role in the disease
development. 
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Elevated levels of lipid peroxidation products and other markers of oxidative stress during the
first week of life have been shown in several studies. Pitkänen et al. (1990) first demonstrated
increased amounts of ethane and pentane in expired air after the first day of life in VLBWI.
This finding was later confirmed in a study, that indicated an inverse correlation between
gestational age and expired air ethane and pentane (Varsila et al. 1994). In a more recent
study, increased pentane production was not significantly related to BPD after the first day of
life but was significantly associated with low gestational age, other complications of
prematurity, such as IVH and ROP, and mortality (Nycyk et al. 1998). Increased
concentrations of urinary and plasma malondialdehyde (MDA) have been reported in preterm
infants with poor respiratory outcome (Schlenzig et al. 1993, Inder et al. 1994, Inder et al.
1996), although the method used, thiobarbituric-acid-MDA, has been criticized because
artificial aldehydes may be generated during sample preparation (Yeo et al. 1994). Higher
concentrations of plasma aldehydes, heptanal, 2-nonenal and 4-hydroxynonenal, were shown
on the first day of life in infants later acquiring BPD, as compared with infants surviving
without BPD. These differences disappeared when the aldehyde concentrations were studied
on days four to six of life (Ogihara et al. 1999).
 Increased levels of protein carbonyls in tracheal aspirates were described in infants
developing BPD, with a negative correlation between gestational age and protein carbonyls
(Varsila et al. 1995). In another study, no significant associations were found between the
levels of oxidant markers in tracheal aspirates and development of BPD. However, a positive
correlation between protein carbonyls and myeloperoxidase, as well as between MDA and
myeloperoxidase, was shown, suggesting a possible contribution by neutrophil-derived ROS
to the lung injury. Further, protein carbonyl level was higher in tracheal aspirates of VLBWI,
than in infants with birth weight exceeding 1500 grams (Buss et al. 2000). The same group
could not demonstrate any association between plasma MDA and protein carbonyls with BPD
or ROP, in contrast to their earlier studies. They speculated that the reason might be that
oxidative stress in these situations is more localized and that elevations in these markers are
diluted in plasma (Winterbourn et al. 2000). A later study showed that protein carbonyl
concentrations in tracheal aspirates during the first three days of life correlated negatively
with gestational age, and that the protein carbonyl concentrations decreased significantly
more in VLBWI who subsequently developed BPD than infants who survived without BPD
(Schock et al. 2001b). A correlation between protein carbonyls and matrix metalloproteinase-
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9, a type IV collagenase, in tracheal aspirates of preterm infants has been reported (Schock et
al. 2001a).
The plasma concentration of allantoin, an oxidation product of uric acid, and the
urate/allantoin ratio have been reported to be higher in infants who later developed BPD
(Ogihara et al. 1996, Moison et al. 1997a). Infants with BPD  had similar levels of plasma
vitamin C as infants without BPD (Moison et al. 1997a), although increased concentrations at
birth have been associated with a high mortality rate and poor outcome in preterm infants
(Silvers et al. 1994). An elevation of the plasma 3-nitrotyrosine level from one day to one
month of age was seen in infants developing BPD, whereas infants without BPD showed no
increase during the same time period (Banks et al. 1998). No studies, except for congress
abstracts, on 8-isoprostane in BPD have been published earlier, but interestingly, an increase
in tracheal aspirate 8-isoprostane concentration was reported in term infants with severe
pulmonary disease (Goil et al. 1998). 
Decreased concentrations of GSH in bronchoalveolar lavage fluid in preterm infants with
respiratory distress (Jain et al. 1995), and in bronchoalveolar lavage fluid (Grigg et al. 1993,
Reise et al. 1997) and in erythrocytes at the age of four weeks (Moison et al. 1997b) have
been shown in preterm infants acquiring BPD.
Pharmaceutical interventions to prevent BPD
During the last decades several trials have been performed in an effort to prevent BPD, with
minimal or no success. Given that ROS are important in the pathogenesis of BPD,
supplementation with antioxidants or their precursors might have potential in preventing the
injury. However, the overall balance of the antioxidant system might be more important than
the level of any of its components, although some of the antioxidants may act as pro-oxidants
if used at high doses (Silvers et al. 1994, Jankov et al. 2001). 
Vitamin A is important for cell growth and differentiation and for the maintenance of
epithelial cell integrity in the respiratory tract. Infants with BPD have lower plasma levels of
vitamin A than their counterparts without BPD (Shenai et al. 1985). The precursors of vitamin
A, the carotenoids, have antioxidant properties. The effect of vitamin A in the prevention of
BPD has been investigated in several studies. The largest study showed a slight decrease in
the incidence of death or BPD at 36 gestational weeks in ELBWI when vitamin A was given
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intramuscularly three times a week over four weeks (Tyson et al. 1999). This was also the
conclusion of a meta-analysis that included seven studies (Darlow and Graham 2003). 
Vitamin E is a chain-breaking antioxidant that inhibits lipid peroxidation. In animal studies, it
has been shown to protect the lungs against oxygen toxicity. However, studies examining the
effect of vitamin E in preventing BPD have failed to demonstrate such an effect (Saldanha et
al. 1982, Watts et al. 1991). In a recent meta-analysis comparing vitamin E supplementation
with placebo, a reduction of severe retinopathy in VLBWI, but no effect on the incidence of
BPD, and even an increased risk of sepsis were found (Brion et al. 2003). However, most of
the studies on vitamin E were performed more than a decade ago, when surfactant or antenatal
steroid treatments were uncommon.
Preterm infants with BPD have lower plasma levels of selenium, an important component of
glutathione peroxidase, than infants without BPD (Darlow et al. 1995). However,
supplementation with selenium did not prevent BPD (Darlow et al. 2000). Treatment with
allopurinol, an inhibitor of xanthine oxidase, during the first week of life also failed to prevent
complications associated with oxidative injury, including BPD (Russell and Cooke 1995).
According to two studies, recombinant human CuZn superoxide dismutase (rhSOD) given
intratracheally repeatedly did not decrease the incidence of BPD, although a reduction in
tracheal aspirate inflammatory markers was found; however, respiratory outcome at the age of
one year was improved in infants treated with rhSOD, suggesting that it may reduce the early
injury of the lung (Davis et al. 1997, 2003). In a baboon model of the old BPD, a synthetic
catalytic antioxidant given intravenously during hyperoxic challenge inhibited the oxygen-
induced alveolar structural remodelling (Chang et al. 2003). 
Besides antioxidant supplementation, other approaches for preventing BPD have been tried.
Corticosteroids have strong anti-inflammatory effects. They have therefore been suggested to
suppress the inflammatory response of preterm infants (Groneck and Speer 1995), and have
been used in several trials aiming at preventing BPD. They have also been widely used in the
routine treatment of severely ill neonates. In addition, by reducing the inflammatory process,
corticosteroid treatment can also reduce the oxidative stress. The results of clinical trials with
dexamethasone have been somewhat controversial (Shinwell et al. 1996, Yeh et al. 1997,
Vermont Oxford Network Steroid Study Group 2001, Stark et al. 2001). Meta-analyses of
postnatal steroid trials concluded that postnatal steroids have some effect on prevention of
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BPD. However, because they also have serious short- and long-term adverse effects, such as
increased risk for cerebral palsy, their use is not recommended as a standard treatment
(Halliday et al. 2003a, 2003b, 2003c). In most of the studies included in the meta-analyses,
dexamethasone was used as a steroid. Preterm infants who develop BPD have been shown to
have impaired glucocorticoid synthesis, and therefore, supplementation with hydrocortisone
might be beneficial (Watterberg et al. 2001). In a pilot study, early treatment with low-dose
hydrocortisone resulted in a better pulmonary outcome (Watterberg et al. 1999). Treatment
with α-1-proteinase inhibitor did not reduce the risk for BPD (Stiskal et al. 1998).
4.   N-acetylcysteine (NAC)
 SH – CH2 – CH – COOH SH – CH2 – CH – COOH
 NHCOCH3                                NH2
              N-acetyl-L-cysteine                Cysteine
Figure 3. Chemical formulae of NAC and cysteine.
N-acetylcysteine (NAC) is a precursor of cysteine (Figure 3). It has a reduced thiol group
which can directly scavenge certain oxidants (Aruoma et al. 1989). However, the major
antioxidant effect of NAC has been ascribed to the increased cysteine availability after its
deacetylation, thus improving GSH and other syntheses (Lauterburg et al. 1983). Rat liver and
lung as well as human liver homogenates deacetylate NAC (Thor et al. 1979, Sjödin et al.
1989). Human endothelial cells are also able to deacetylate NAC and utilize the liberated
cysteine in intracellular GSH synthesis. This mechanism may contribute to the metabolic
clearance of intravenously administered NAC and also supply NAC-derived cysteine to other
cells (Cotgreave et al. 1991). NAC appears to support GSH synthesis in situations where the
need for GSH is increased, but it might not have an effect on plasma GSH if there is no need
for increased GSH production (Burgunder et al. 1989).
Administration of GSH does not increase intracellular GSH levels because GSH has to be
metabolized extracellularly before it can be taken up by most cells (Meister 1991). GSH given
as an aerosol increased GSH levels in ELF, but intracellular levels were not augmented (Buhl
et al. 1990). Administration of cysteine, the rate-limiting amino acid in GSH synthesis, also
does not increase intracellular GSH since cysteine is readily oxidized to cystine, which has
low solubility. More importantly, cysteine has been reported to be toxic to neurons (Puka
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Sundvall et al. 1995), possibly through the generation of OH.   during autoxidation (Wang and
Cynader 2001). The optimal compound for antioxidant therapy in preterm infants would
therefore be a stable cysteine precursor that gets into the cell and is safe for clinical use. 
NAC has been in clinical use for more than 40 years. It is used as a mucolytic agent in chronic
bronchitis and other pulmonary diseases (Grassi and Morandini 1976). In paracetamol
(acetaminophen) poisoning, which is associated with GSH depletion, it is the treatment of
choice as an antidote either orally or intravenously (Flanagan and Meredith 1991). Thus, there
is extensive clinical experience, also in paediatrics, on the use of NAC. Furthermore, it has
been studied in the treatment of pulmonary oxygen toxicity and adult respiratory distress
syndrome, as well as in both acute and chronic inflammation. Its effects in the treatment of
different disorders involving the immune system, such as HIV infection, have also been
explored (Herzenberg et al. 1997). In recent years, NAC has been used as a tool in research on
apoptosis and gene transcription (Cotgreave 1997). 
The adverse drug reactions of NAC reported in the literature have been related to high doses
or polypharmacy (Mant et al. 1984). Anaphylactoid reactions, including rash, flushing,
urticaria, bronchospasm and angioedema, mostly associated with very high doses of NAC
(more than 10 times the dose used in this trial) have been described in adults (Prescott et al.
1989). Myocardial depression was observed in one study (Peake et al. 1996). However, others
have found a positive effect on cardiac function (Harrison et al. 1991, Spies et al. 1994).
Hypotension caused by a decrease in systemic vascular resistance has also been described and
can be treated symptomatically without discontinuation of infusion. Shortening of
prothrombin time and inhibition of platelet function were reported in one study in adults
(Jepsen et al. 1992). In another study, where NAC, streptokinase and nitro-glycerine were
administered for acute myocardial infarction, minor bleeding problems were described
(Arstall et al. 1995).
Pharmacokinetics of NAC
The interpretation of different pharmacokinetic studies of NAC is somewhat difficult due to
the different analytical methods, doses, formulations and route of administration used. NAC
can be present in plasma in free form or bound to proteins (Holdiness 1991). The
bioavailability of NAC after an oral dose is low, 4-10% (Borgström et al. 1986, Olsson et al.
1988), due to deacetylation during first-pass metabolism in the small intestine and liver.
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However, oral  NAC has been shown to support GSH synthesis when the demand for GSH is
increased, as in paracetamol intoxication (Burgunder et al. 1989). Further, increased
concentrations of cysteine in plasma, and GSH in plasma and airways were found after oral
administration of NAC (Bridgeman et al. 1991). After intravenous administration of NAC, a
mean terminal half-life of about six hours, a mean volume of distribution of 0.47-0.54 l· kg-1
and a mean plasma clearance of 0.11-0.19 l·h-1·kg-1 have been reported (Olsson et al. 1988,
Prescott et al. 1989). About 20-30% of the intravenous dose is excreted unchanged in the
urine (Olsson et al. 1988).
Experimental evidence supporting the use of NAC in lung injury
In vitro studies have shown that NAC efficiently scavenges HOCl, thus protecting α1-
antiproteinase against inactivation. It also reacts rapidly with OH·  and slowly with H2O2, but
not to any major extent with O2·- (Aruoma et al. 1989). Preincubation with NAC protected
type II alveolar epithelial cells from HOCl- and H2O2-mediated sublethal injury and loss of
intracellular ATP stores (Pacht and Abernathy 1995). NAC has also been reported to inhibit
IL-8 secretion by IL-1α-stimulated bronchial epithelial cells (Matsumoto et al. 1998). Oral
NAC treatment in healthy persons decreased the production of O2·- by stimulated neutrophils
and improved their phagocytic capacity without an effect on their random or chemotactic
migration. The GPx level of thrombocytes also increased as compared with levels before
treatment (Urban et al. 1997).
In animal studies, NAC has been shown to prevent hyperoxic lung injury in preterm guinea
pigs, although it did not elevate GSH levels in the lung or liver (Langley and Kelly 1993). In a
rat model of lung injury, NAC attenuated the endotoxin-induced increases in lung
permeability and lipid peroxidation. However, intracellular GSH levels did not increase, and
the effect was assumed to be mediated by the free radical scavenging properties of NAC
(Davreux et al. 1997). Hyperoxic exposure of rats prior to liver perfusion is associated with a
decrease in hepatic GSH, and NAC administration during the hyperoxic exposure has been
demonstrated to increase in a dose-dependent manner the GSH concentrations in bile, liver
and perfusate (Shattuck et al. 1998). 
Clinical applications of NAC in lung injury
In addition to its use as a mucolyte and as an antidote in paracetamol poisoning, NAC has
been studied in several situations where the levels of GSH decrease or oxidative stress is
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implicated (Kelly 1998). In adult respiratory distress syndrome (ARDS), the GSH levels
decrease, but the depletion can be reversed by NAC in plasma and erythrocytes (Bernard
1991), as well as in granulocytes (Laurent et al. 1996). However, the sample sizes have been
small in these studies and results have been either inconclusive or conflicting. In some
studies, even though NAC did not have any effect on mortality, it improved lung function and
systemic oxygenation and enhanced recovery from ARDS (Jepsen et al. 1992, Suter et al.
1994, Bernard et al. 1997). However, contradictory results have also been reported
(Domenighetti et al. 1997).
In patients with pulmonary fibrosis, administration of intravenous NAC increased the total
glutathione concentration of ELF, which did not occur in healthy controls (Meyer et al. 1995).
The same effect on GSH in ELF as well as improvement in pulmonary function tests was seen
in patients with fibrosing alveolitis when treated with high-dose oral NAC for 12 weeks (Behr
et al. 1997).  
A rational way of improving the antioxidant defences of preterm infants would be to increase
intracellular GSH levels by NAC administration, since in this patient group cysteine supply is
limited (van Goudoever et al. 1995, Viña et al. 1995). In preterm infants, NAC has been used
intratracheally as a mucolytic agent to treat BPD, but in a small (n=10) randomized, placebo-
controlled trial NAC did not improve clinical condition or hasten recovery, but did increase
airway resistance, causing cyanotic spells in some infants (Bibi et al. 1992). Treatment of
paracetamol overdose with NAC has been reported in one preterm infant (Isbister et al. 2001).
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AIMS OF THE STUDY
Oxidative stress is considered to play a role in the pathogenesis of several complications of
prematurity, among which BPD is one of the most important causes of long-term morbidity
after preterm birth (Jobe and Bancalari 2001). Immature infants have a relative glutathione
deficiency, which increases with decreasing gestational age (Jain et al. 1995). Glutathione is
important in antioxidant defence both as a direct scavenger of  ROS and as a co-substrate in
peroxidase reactions. Thus, a deficiency in glutathione system may impair antioxidant
defences in the preterm infant. We hypothesized that NAC would decrease morbidity and
mortality in preterm infants because of its direct antioxidant effects and its ability to increase
intracellular glutathione concentrations. The objective of this project thus was to investigate
the role of NAC in the prevention of ROS-related complications in preterm newborn infants.
The specific aims were: 
1) to determine the pharmacokinetics of intravenously administered NAC in preterm
neonates,
2) to assess whether NAC infusion during the first week of life reduces the risk of death or
BPD in ELBWI,
3) to find a suitable risk indicator for oxidative stress in ELBWI,
4) to measure thiol metabolism during the first week of life in preterm neonates,
5) to investigate the effect of NAC on indicators of oxidative stress.
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SUBJECTS AND METHODS
1.   Study designs
A primary pharmacokinetic study was performed in one centre, the Hospital for Children and
Adolescents, Helsinki University Central Hospital, to investigate the pharmacokinetics of
NAC in preterm infants during a one-day infusion. A second one-centre pharmacokinetic
study was performed that applied the results of the first study and aimed at a steady-state
plasma NAC concentration to determine whether an accumulation of NAC occurs during
prolonged administration.
Based on the pharmacokinetic studies, an NAC treatment regimen was applied in a
multicentre, randomized, controlled trial (RCT) on ELBWI to investigate whether it decreases
the incidence of BPD and other complications of prematurity and mortality. The study was
double-blind, randomized and stratified in blocks of 10 for each centre. The RCT was carried
out at 10 academic neonatal intensive care units in Denmark, Finland, Iceland, Norway and
Sweden. 
A one-centre subgroup of infants from the Hospital for Children and Adolescents, Helsinki
University Central Hospital, were studied for the following markers of oxidative stress: 8-
isoprostane and ascorbyl radical, and for plasma and erythrocyte thiols and glutathione
metabolism-related enzymes.
2.   Study populations
In the two pharmacokinetic studies, newborn infants with a birth weight of 500-1500 g and a
gestational age between 24 and 32 weeks were eligible to participate, if they required assisted
ventilation. Ten infants participated in the first and six in the second pharmacokinetic study.
In the RCT, a total of 397 infants with a birth weight of 500-999 g, who were on ventilator or
nasal continuous positive airway pressure were enrolled before the age of 36 h. Children with
major congenital anomalies were excluded. Six infants were excluded from the analyses, one
because of parental refusal, and five because of major congenital anomalies diagnosed after
the enrolment (1 transposition of great arteries, 2 tetralogy of Fallot, 1 major ventricular septal
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defect and 1 anal atresia) (Figure 4). During the study period from March 1997 to April 2001,
a total of 126 infants were enrolled in Helsinki, 45 in Lund, 49 in Gothenburg, 36 in
Stockholm, 60 in Copenhagen, 23 in Aarhus, 21 in Aalborg, 26 in Reykjavik, 3 in Oslo and 8
in Trondheim.
Figure 4. Recruitment of extremely low birth weight infants in the randomized clinical trial.
The plasma samples for 8-isoprostane measurements were obtained from 83, and for ascorbyl
radical determinations from 61 infants of the group (n=123) enrolled in the RCT. Infants with
adequate samples on days 3 and 7 were included. The baseline characteristics of the study
group infants did not differ from the other infants of the centre or from the total study
population (n=391) with the exception of intrauterine growth retardation; 46% of the infants
in the study group were small for gestational age (SGA) compared to 38% in the entire trial
population. When classified according to the main outcome, BPD or died at the age of 36
gestational weeks vs. no BPD, the baseline characteristics were similar with the exception of
birth weight; infants who survived without BPD weighted significantly more (p<0.05). No
Randomized (n=397)
N-acetylcysteine (n=196) Placebo (n=201)
Received NAC treatment
as allocated
(n=192)
Did not receive NAC
treatment as allocated
(n=3, intention-to-treat)
Received placebo
treatment as allocated
(n=195)
Did not receive placebo
treatment as allocated
(n=3, intention-to-treat)
Excluded (n=2) Excluded (n=4)
Followed up to 28 days,
secondary outcomes
(n=194)
Followed up to 28 days,
secondary outcomes
(n=197)
Followed up to 36
gestational weeks,
primary outcomes
(n=194)
Lost to follow-up (n=0)
Followed up to 36
gestational weeks,
primary outcomes
(n=196)
Lost to follow-up (n=1)
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differences were present in the baseline characteristics of infants with or without PVL. The
incidence of maternal infection and postnatal sepsis was similar.
In the study of thiol metabolism during the first week of life, blood samples were collected
from 26 infants with a birth weight of 1000-1500 g admitted to the neonatal intensive care
unit at the Hospital for Children and Adolescents, Helsinki University Central Hospital,
between July 1997 and January 1998, if they had an indwelling arterial catheter for clinical
reasons, and from 52 ELBW infants participating in the placebo-arm of the RCT. Nineteen
infants in the 1000 to 1500-g group and 34 in the 500 to 999-g group were appropriate for
gestational age (AGA, birth weight within 2SD).
3.   Drug administration and patient care
In the first pharmacokinetic study, NAC (N-acetyl-L-cysteine, 200 mg/ml, Parvolex®, Evans,
UK) was infused at a mean constant rate of 4.2 (range 3.4-4.6) mg/kg/h. The range was due to
the infusion pump accuracy (0.1 ml/h). NAC infusion was started as soon as possible after
birth (range 2.0-11.2 h) and lasted for 24 (range 18.9-26.7) h. In the second pharmacokinetic
study, NAC was infused at a constant rate of 0.3-1.3 mg/kg/h; the smallest infants received
the lowest doses. The infusion was started at the age of 24 h (± 15 min) and lasted for 6 days. 
In the RCT, the infants received either intravenous NAC (N-acetyl-L-cysteine, 200 mg/ml,
Mucomyst®) or placebo. The NAC and placebo vials were supplied free of charge by Draco
Läkemedel AB (AstraZeneca, Sverige AB), Sweden. The NAC vials were diluted 1:100 to a
final concentration of 2 mg/ml with 5-30% glucose solution, depending on the glucose
requirement of the infant. The dilution procedure for the placebo infusion was identical. The
infusion was started before the age of 36 h and lasted for 6 days at a constant rate of 16-32
mg/kg/d (i.e. 0.7-1.3 mg/kg/h), which was calculated on the basis of birth weight, the smallest
infants receiving the lowest doses. This dosage was based on the results of the
pharmacokinetic studies and aimed at a steady-state plasma concentration of 100-300 µmol/l.
The target concentration was based on a clinical study in adults with myocardial infarction
(Arstall et al. 1995), showing beneficial effects of N-acetylcysteine at a mean plasma level of
172 µmol/l, and on our unpublished work on cultured cells exposed to oxidants.
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The patients were treated according to the routine procedures in each intensive care unit, and
received parenteral and usually some enteral nutrition. However, amino acid solutions were
not infused during the first pharmacokinetic study. In the second pharmacokinetic study and
the RCT, intravenous amino acids (Vaminolac®, Fresenius-Kabi, Uppsala, Sweden,
containing 1 mg/ml cysteine+cystine) were started on day 1 or 2. The first dose was 8
ml/kg/d, increasing daily up to 40-60 ml/kg/d. 
4.   Safety and monitoring
Blood pressure, heart rate and oxygen saturation were monitored continuously during the
study periods, with special attention on the mean arterial blood pressure during the 1 h prior
to and the first 6 h after the start of the infusion. The skin was carefully checked at least three
times daily to note any skin reactions.
To register possible side-effects caused by NAC, laboratory parameters, including white
blood cell count, thrombocytes, alanine aminotransferase, international standardized ratio of
thromboplastin time and serum urea levels were followed at least once during the
pharmacokinetic studies, and several times during the first 2 weeks in the RCT. Haemoglobin
concentration was measured daily during the pharmacokinetic studies, and less frequently
during the RCT, to detect possible bleeding. Complications, although not necessarily related
to the NAC treatment, were recorded daily during the first 2 weeks of the RCT, and severe
adverse events were reported immediately, until the age of 36 gestational weeks, according to
the requirements of the pharmaceutical company who supplied the vials.
The steering group of the RCT was informed as soon as possible when a patient was enrolled,
died or reached the gestational age of 36 weeks, thus completing the trial. Unexpected and
severe adverse events as well as suspected adverse effects and drop-outs were to be reported.
Each centre received sealed emergency envelopes for each infant revealing the code of the
treatment allocation. The code was broken in two cases, once in a severe adverse event, and
once after an incorrect dosage of the study medicine was given. The steering group was
appropriately informed on both occasions. The steering group passed on relevant information
to the monitoring and safety group, who continuously monitored the main outcome measures.
One interim analysis was carried out for safety after the enrolment of 40 patients in the main
centre (Hospital for Children and Adolescents, Helsinki University Central Hospital). One
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member of the steering group performed on-site visits to the other centres to monitor
adherence to the protocol and assess accuracy.
5.   Clinical data, outcome measures and follow-up 
In the RCT, follow-up data were collected in each centre on specific data collection forms
designed for the study (Figure 5). The primary outcome was death or BPD at an age
corresponding to 36 gestational weeks. BPD was defined as any supplementary oxygen
requirement at 36 gestational weeks. Secondary outcome measures were requirement of
supplemental oxygen at the age of 28 days, duration of ventilator or nasal continuous positive
airway pressure treatment, weight gain and the incidence of other ROS-related diseases,
including IVH, PVL, NEC and ROP. 
Ultrasound examinations of the brain were performed at least once during the first week and
at the age of 28 days on the infants in the RCT. Traditional classifications were used for
IVH(Papile et al. 1978) and PVL (Trounce et al. 1986). The radiological severity of BPD in
the RCT was assessed from chest x-rays taken at the age of 28 days and 36 gestational weeks
by one radiologist using two classifications (Toce et al. 1984, Weinstein et al. 1994). The
clinical severity of BPD was classified according to a recent proposal (Jobe and Bancalari
2001).
The evaluation of ROP was performed at the gestational age of 36 weeks by an
ophthalmologist. The grading of retinopathy was classified according to the stage of the
disease in the more severely affected eye (Committee for the Classification of Retinopathy of
Prematurity 1984). NEC was registered if it was of grade III or higher, i.e. NEC needing
surgical treatment (Bell et al. 1978).
6.   Biochemical analyses
Blood sampling
In the pharmacokinetic studies, arterial blood samples (0.2 ml) were taken from an indwelling
arterial catheter into heparin-coated test tubes. In the first study, the samples were taken
immediately before the infusion (0 h), at 1, 2, 6, 12 and 24 h after the start of the infusion and
at 1, 2, 4, 6, 12 and 24 h after the end of the infusion. In the second study, the samples were 
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     FLOW CHART
Eligibility check-list
                                ↓                                                                                            
Obtain written, informed consent from
parents
Consent not obtained: fill in Appendix H and
send it to Helsinki
                                ↓ 
Open the next consecutively case-numbered
pack and fill in the registration form
                                ↓  
Send (using fax) the 
registration form and the
consent form to Helsinki
                                ↓
Age 0-36 h Blood samples
Ventilator settings
Start the trial infusion
as soon as possible after birth before the age
of 36 h
Fill in Appendix E:
at the enrolment
at the age of 0-36 h 
See Appendix A for instructions for
preparation of trial solution
                                ↓      
Age 60-84 h Blood samples
Ventilator settings
Fill in Appendix E:
at the age of 60-84 h
                                ↓
7th day
(age 144-168 h) 
Blood samples 
Ventilator settings
Weight
Ultrasound of the brain
Fill in Appendix E:
7th day
                                ↓
Age 2 weeks Blood samples
Ventilator settings
Weight
Fill in Appendix E:
at the age of 2 weeks
                                ↓
Age 4 weeks
(27-30 days)
Blood samples
Ventilator settings
Weight
Chest x-ray (label ”28”)
Ultrasound of the brain
Fill in Appendix E:
at the age of 4 weeks
                                ↓  
Age 36
conceptional
weeks
Blood samples
Ventilator settings
Weight
Chest x-ray (label ”36”)
Ultrasound of the brain
Ophthalmologist
Fill in Appendix E:
at the conceptual age of 36 weeks
Return the collection forms (Appendix E) and
X-rays ”28” and”36” to Helsinki
                                ↓
Age 1.5 years
(corrected age)
Follow-up Fill in Appendix I and send it to Helsinki
Figure 5. Flow chart of the RCT. Blood samples included samples for haemoglobin, white blood cell count,
thrombocytes, alanine aminotransferase, international standardized ratio of thromboplastin time and serum urea
measurements, and in addition on days 3 and 7 samples for NAC, cysteine and glutathione analysis. Data were
collected in Appendices A-I.
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taken immediately before and at 12, 24, 48, 72, 96, 120 and 144 h after the start of the
infusion. Actual sampling times were registered and calculations were based on these values.
Plasma was separated within 15 min and stored frozen at -70°C until analysed. In the RCT,
routine laboratory tests were performed according to the local customs in each centre. To
assure compliance and to evaluate drug metabolism, blood samples of at least 0.5 ml of
plasma were obtained from an indwelling catheter in standard heparin-coated test tubes at the
age of 60-84 hours and at the age of 6-7 days, just before terminating the infusion. These days
were chosen to ensure that the plasma NAC level remained stable during the study. Plasma
was separated and both plasma and erythrocytes were stored frozen at -70°C until the
samples were analysed in Helsinki. The samples from RCT infants enrolled in Helsinki were
also used for determination of 8-isoprostane and ascorbyl radical levels, and for the study of
thiol metabolism.
For the determination of the activities of glutathione cycle enzymes, as well as thiol
metabolism in the VLBWI, arterial blood samples (0.3-0.4 ml) for blood acid-base status
determination on clinical indication were obtained from the arterial line at the age of 0-6 h
(day 0), 18-30 h (day 1), 60-84 h (day 3), and 144-168 h (day 7). After the immediate
measurement of acid-base balance, the remaining blood in the syringe (0.1-0.3 ml) was
centrifuged, and plasma and erythrocytes were separated and stored frozen at -70°C until
analysed.
Plasma and erythrocyte thiols
Concentrations of NAC in plasma, and glutathione and cysteine in plasma and erythrocytes
were analysed by high-performance liquid chromatography (HPLC) with penicillamine as the
internal standard (Cotgreave and Moldéus 1986). Briefly, disulphides were first reduced by
dithiotreitol to sulfhydryls, which were then derivatized with monobromobimane. For this
reason, the reported values are for total NAC, glutathione and cysteine, which include various
NAC, glutathione- and cysteine-containing disulphides in addition to free monomers. A
reversed-phase C-18 column was used to separate the adducts, and quantitation was
performed using a fluorescence detector.
Free 8-isoprostane
Plasma free 8-isoprostane concentration was measured without purification with a
commercial enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA). The
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samples were assayed in a 96-well plate coated with mouse anti-rabbit IgG monoclonal
antibody to 8-epi-prostaglandin F2α. An 8-epi-prostaglandin F2α tracer bound to
acetylcholinesterase was used to compete for binding sites. Samples were assayed at 50 µl
and read at 420 nm in a 96-well microplate reader (Multiscan EX, Thermo Labsystems Oy,
Vantaa, Finland). The range of the standard curve was from 3.9 to 500 pg/ml.
Ascorbyl radical 
The intensity of the ascorbyl radical signal in 0.2 ml of plasma was measured with a Bruker
ECS 106 ESR spectrometer. Spectrometer settings were as follows: Field centre: 3478.5
Gauss, Modulation amplitude: 1.0 Gauss, Microwave power: 10 mW, Microwave frequency:
9.74 GHz, Scan range: 10 Gauss, Scan rate: 60 Gauss/min, Time constant: 0.02 s. The
intensity of the signal is displayed as arbitrary units and is proportional to the amount of
radicals in the sample.
 
Erythrocyte glutathione cycle enzymes
Erythrocytes were haemolysed by addition of 10 volumes of cold distilled water, and the
ghosts were removed by centrifugation at 14 000 g for 10 min. Haemoglobin was determined
as cyanomethaemoglobin (Tentori and Salvati 1981). Spectrophotometric assays were used to
measure GPx, GR, GST and G6PDH activities from the haemolysates. GPx activity was
analysed by measuring NADPH oxidation in the presence of t-butylhydroperoxide,
glutathione and GR (Beutler 1975a), and GR activity by measuring the oxidation of NADPH
in the presence of oxidized glutathione (Beutler 1975b). GST activity was analysed by the
CDNB-method (Habig et al. 1974). G6PDH activity was measured by following the reduction
of NADP in the presence of glucose-6-phosphate (Löhr and Waller 1974). One unit (U)
corresponds to reduction/oxidation of 1 µmol of NAD(PH) per minute. GCL was assayed
using HPLC method with fluorometric detection (Nardi et al. 1990, Levonen et al. 2000b).
One unit (U) corresponds to 1 µmol of glutamyl-cysteine formed per minute.
7.   Statistics
The sample size calculation for the RCT was based on the statistics over a 2-year period from
1993 to 1995, in the Hospital for Children and Adolescents, Helsinki University Central
Hospital, which showed that 46% of babies weighing less than 1000 g at birth either died or
developed BPD by the time they reached the age of 36 gestational weeks. To detect a 33%
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reduction in BPD or death with NAC treatment with a power of 80% and a significance level
of 5% with a two-tailed test, the sample size was estimated to be 180 in each group. To
compensate for the estimated drop-out rate of 10%, we decided to recruit 396 infants.
All data were analysed using the SPSS 10.0 statistical package (SPSS Inc., Chicago, IL,
USA). All normally distributed data are expressed as mean ± SD. Correlations were analysed
by Spearmans rank correlation test. Baseline data for the treatment groups were compared
using the t-test for continuous variables or the Mann-Whitney U-test, as appropriate.
Categorical baseline characteristics and outcomes were analysed using the χ2-test. All
statistical tests were two-tailed. Statistical significance was set at p<0.05. 
In the pharmacokinetic studies, the elimination rate constant (kel) of NAC was determined by
linear regression analysis of the log-linear concentration versus time curve. The elimination
half-life (t1/2) of NAC was calculated from the equation: t1/2 = ln 2/kel, and the plasma
clearance (CL) and volume of distribution (Vd) were calculated according to standard
formulae (Gibaldi and Perrier 1982). 
In the RCT, all data for eligible enrolled infants were analysed on an intention-to-treat basis.
Logistic regression was used to analyse the outcomes. The results of 8-isoprostane analyses
are given as medians and ranges because of the skewness of the values. The 8-isoprostane
data were log-transformed before statistical analysis where appropriate. General Linear Model
ANOVA for repeated measures was used to determine differences in 8-isoprostane and
ascorbyl radical levels between the groups. One-way ANOVA using Fishers least significant
difference test was applied for thiol data (IV). 
8.   Ethical considerations
The National Agency for Medicines, Finland, was appropriately informed before the
pharmacokinetic studies were performed. All study protocols were approved by the Research
Ethics Committee of the Hospital for Children and Adolescents, Helsinki University Central
Hospital, and in the RCT by the Research Ethics Committees of participating institutions and
the national authorities of each country. Informed parental consent was obtained for each
infant prior to enrolment in the clinical trials. 
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The blood samples in this project were obtained at the same time as those on clinical
indication. All samples were obtained from an indwelling catheter to minimize pain, or in the
RCT, if there was no catheter, only results of blood tests taken for clinical purposes were
used. The amount of blood needed for research was minimized. Furthermore, if the infant
received erythrocyte or plasma transfusions for clinical purposes, the blood withdrawn for
research samples was compensated. NAC infusion was given together with intravenous
nutrition as a side-infusion, and no extra catheters were needed. All monitoring and other
examinations, such as x-rays and ultrasound of the brain, are performed routinely during the
intensive care of preterm infants, and these results were used also for clinical purposes.
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RESULTS
1.   Pharmacokinetics of NAC in preterm infants (I)
When NAC was infused intravenously with a mean rate of 4.2 (range 3.4-4.6)g/kg/h, the steady-
state concentration of NAC was not reached during the first 21-24 hours (I, Figure 1). The mean
plasma NAC concentration at the end of the infusion was 510 (range 380-770) µmol/l. The
average t1/2 of NAC was 11.0 (range 7.8 - 15.2) h, its clearance (CL) ranged from 13 to 62 ml/kg/h
and its volume of distribution (Vd) from 167 to 1010 ml/kg. The CL and Vd, but not t1/2, of NAC
correlated well with weight (r=0.81, p<0.01, and r=0.78, p<0.01, respectively), and with
gestational age (r=0.71, p<0.05, and r=0.64, p<0.05, respectively). The weight of infants in this
group correlated only weakly with gestational age (r=0.56, p<0.1). The median plasma cyst(e)ine
concentration decreased from the initial level of 120 (range 56-188) µmol/l for 24 h, remained
relatively stable for the next 24 h, and increased thereafter (I, Figure 3, upper panel). 
When NAC was infused continuously for 6 days, the steady-state concentration of plasma NAC
was reached in five out of the six patients within 50-70 h after the beginning of the infusion. The
steady-state concentration of NAC in these infants ranged from 60 to 203 µmol/l at a constant
infusion rate of 0.3-1.2 mg/kg/h (I, Figure 2). The plasma clearance of NAC in these newborns
ranged from 20 to 42 ml/kg/h. In one patient (infusion rate 1.3 mg/kg/min), the concentration kept
rising during the 6-day period. The median plasma cyst(e)ine concentrations remained around 120
µmol/l for the duration of the study (I, Figure 3, lower panel).
 
2.   Effect of NAC in preventing BPD and other complications of prematurity (II)
In total, 391 infants participated in the RCT, 194 in the NAC group and 197 in the placebo group.
The baseline characteristics (II, Table 1) and respiratory status before the treatment were similar in
both groups (Figure 6). NAC treatment had no effect on the combined incidence of the primary
end-points, death or BPD at the age of 36 gestational weeks, which was 51% in the NAC group
and 49% in the control group. The incidence of BPD in survivors was 40% in both groups, and no
difference in BPD severity was seen between the groups (II, Figure 1). Mortality at the age of 36
gestational weeks was 18% in the NAC group and 14% in the control group (Figure 7).
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Figure 6. Respiratory status of infants Figure 7. Primary outcome of the RCT, defined as
participating in the RCT before the treatment. death or BPD at the age of 36 gestational weeks.
No differences were present between the groups. No differences were present between the groups.
OI=oxygenation index x100, 
FiO2=fraction of inspired oxygen.
NAC treatment had no effect on mortality or on the need for supplemental oxygen at the age of 28
days (II, Table 2). The incidences of other oxidative stress-related complications of prematurity,
such as IVH, NEC, PDA, PVL or ROP, did not differ significantly between the groups, although
the incidence of PVL was 39% higher in the control group (Figure 8). The incidences of the other
complications of prematurity in the infants who died, or survived with or without BPD are
presented in Figure 9.
Figure 8. Incidences (%) of secondary outcomes, 
other ROS-related complications of prematurity.
No differences between the groups. 
Duration of ventilatory support, use of postnatal steroids, mean percentage of oxygen required at
the age of 28 days and weight gain from birth to the age of 36 gestational weeks were similar in
both groups. Neither laboratory parameters nor blood pressure levels differed between groups.
Although adverse events during intensive care were seen as expected in ELBWI, none could be
ascribed to NAC treatment. 
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Figure 9. The incidences of other complications of prematurity in the infants who either died or survived with or
without BPD.
Chest x-rays from 260 infants at the age of 28 days and from 230 infants at the age 36 gestational
weeks, scored according to two different methods (Toce et al. 1984, Weinstein et al. 1994) and by
the subjective evaluation of a senior paediatric radiologist showed no difference between the
groups. 
Mean plasma concentrations of NAC, cysteine and glutathione are presented in Figure 10. The
mean plasma cysteine concentration was significantly lower in the NAC group (p<0.01)and
increased significantly in both groups from day 3 to day 7 (p<0.001), but NAC had no significant
effect on the change. The mean plasma glutathione concentration was also lower in the NAC
group (p<0.01), but it did not change significantly from day 3 to day 7 in either group. In infants
who survived without BPD, the plasma cysteine concentration was higher regardless of the
treatment, but plasma glutathione concentration did not differ significantly. 
Figure 10. Plasma concentrations of NAC, cysteine and glutathione on day 3 and day 7 in NAC- and placebo-
treated infants. 
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3.   Plasma free 8-isoprostane and ascorbyl radical as markers of oxidative stress (III)
The median (range) 8-isoprostane concentration was significantly higher on day 3 and day 7 in
infants who later developed BPD or died (n=29), 50.0 (19-360) pg/ml and 57.0 (14-460) pg/ml,
respectively, as compared with infants who did not develop BPD (n=54), 34.5 (5-240) pg/ml and
39.5 (7-400) pg/ml, respectively, (p=0.05) (Figure 11A). The level of 8-isoprostane correlated
positively with the severity of BPD. 
In infants with severe (grade 3-4) IVH (n=10), the median 8-isoprostane concentrations differed
significantly from those without IVH; on day 3 it was 67.5 (29-190) pg/ml  and 36 (5-360) pg/ml,
respectively, and on day 7, it was 81 (18-490) pg/ml  and 44 (7-360) pg/ml, respectively, (p<0.01)
(Figure 11B). In infants who later developed PVL (n=8), as compared with infants who did not,
the median 8-isoprostane concentration on day 3 was similar, 39 (5-360) pg/ml vs. 39.5 (30-240)
pg/ml, but was significantly increased on day 7, 40 (7-460) pg/ml vs. 80 (45-400) pg/ml (p<0.05)
(Figure 11C). No differences were present in 8-isoprostane levels in infants with or without NEC,
ROP or postnatal sepsis (verified by positive blood culture). 
 Figure 11. Plasma free 8-isoprostane levels in ELBWI who had BPD or died (A) as compared with those who
survived without BPD, in ELBWI with or without severe grade 3-4 IVH (B), with or without PVL (C). Plasma
ascorbyl radical levels in ELBWI with and without PVL (D). Isoprostane data are expressed as mean (SD) of the
log10 transformation of plasma concentrations in pg/ml, ascorbyl radical data as mean (SD) in arbitrary units.
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The plasma mean ascorbyl radical level decreased significantly from day 3 to day 7. Developing
BPD did not significantly influence these levels, but in infants who later developed PVL, the
ascorbyl radical level was significantly higher on day 3 (p<0.01) (Figure 11D). NAC treatment
had no effect on plasma free 8-isoprostane or ascorbyl radical levels.
4.   Thiol metabolism and erythrocyte glutathione cycle enzymes in preterm infants not
receiving NAC (IV)
In the study of thiol metabolism, significant (p<0.01) initial increase occurred in mean plasma
glutathione concentration from day 0 to day 1, followed by a decrease towards the end of the first
week of life. The change in plasma cysteine concentration was the reverse, with an initial decrease
from day 0 to day 1 (p<0.01), followed by an increase (IV, Figure 1 A-B). Interestingly, in infants
without RDS, the decrease was not statistically significant (Table 2). In infants who were
appropriate for gestational age, a significant positive correlation was observed between plasma
cysteine and gestational age on day 1 (R=0.55, p=0.01). The difference between genders was not
statistically significant. 
Erythrocyte glutathione concentration decreased during the first week, whereas erythrocyte
cysteine concentration increased significantly from day 3 to day 7 (p<0.01). (Table 2), (IV, Figure
1C-D). Erythrocyte glutathione and cysteine concentrations showed a positive correlation, but no
correlation between plasma and erythrocyte glutathione or cysteine concentration was seen.
In infants with RDS, the plasma glutathione concentration was significantly lower on day 0, as
compared with those without RDS (p<0.01). Interestingly, infants, who later developed BPD or
died had a significantly higher plasma glutathione concentration on day 1 (p<0.05) and a lower
plasma cysteine concentration on day 7 (p<0.05) than those who survived without BPD. No
difference in plasma cysteine concentrations were seen in RDS, but the erythrocyte cysteine
concentration was lower on day 0 compared with infants without RDS. Infants who later
developed BPD or died had a significantly lower erythrocyte cysteine (p<0.05) and glutathione
concentration on day 1 (p<0.05) than those who survived without BPD (Table 2) (IV, Figures 2
and 3).
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Table 2. Mean (SD) plasma and erythrocyte cysteine and glutathione concentrations 
in VLBW and ELBW infants during the first week of life.
day 0 day 1 day 3 day 7
Plasma cysteine (µmol/l)
   all infants 173 (60) 129 (42) ** 142 (44) * 206 (63) *
   infants without RDS 169 (44) 143 (51) 157 (44) 226 (82) *
   infants with RDS 175 (67) 121 (35) ** 137 (44)* 200 (57)
   infants without BPD 179 (63) 131 (44) ** 150 (41) * 218 (65) *
   infants with BPD 145 (30) 123 (38) 128 (47) 176 (49) 
Plasma glutathione (µmol/l)
   all infants 15 (7) 28 (12)  27 (9)  22 (6) **
   infants without RDS 21 (6) 32 (15) * 27 (4) 23 (5)
   infants with RDS 12 (5) 25 (9) 27 (10) 22 (6)
   infants without BPD 15 (7) 27 (13) ** 27 (9) ** 21 (5) *
   infants with BPD 13 (6) 32 (5)  27 (7) ** 25 (7) **
Erythrocyte cysteine (µmol/gHb)
   all infants 0.10 (0.03) 0.10 (0.05) 0.09 (0.04) 0.12 (0.06) 
   infants without RDS 0.12 (0.03) 0.12 (0.06) 0.09 (0.03) 0.15 (0.08)
   infants with RDS 0.09 (0.03) 0.10 (0.05) 0.09 (0.04) 0.11 (0.05)
   infants without BPD 0.10 (0.02) 0.11 (0.05) 0.09 (0.04) 0.12 (0.06) 
   infants with BPD 0.09 (0.05) 0.08 (0.04) 0.09 (0.03) 0.12 (0.06) 
Erythrocyte glutathione (µmol/gHb)
   all infants 8.2 (0.9) 8.0 (1.9) 6.9 (1.5) ** 6.6 (1.3) **
   infants without RDS 8.5 (0.9) 8.6 (3.2) 7.7 (2.5)  7.0 (1.1) 
   infants with RDS 8.1 (0.9) 7.7 (0.9) 6.7 (1.0)  6.5 (1.4) 
   infants without BPD 8.3 (1.0) 8.4 (2.1) 7.0 (1.7) ** 6.6 (1.5) 
   infants with BPD 7.9 (0.5) 7.0 (0.8) 6.7 (1.0) ** 6.6 (0.8) **
*= p<0.05, ** = p<0.01, =p<0.001 compared with day 0
=p<0.01 compared with day 3.
The erythrocyte glutathione cycle enzymes activities during the first week of life are presented in
study IV (Figure 4A-E). The activities of GST and G6PDH decreased during the first week, but no
change in the activities of GCL and GR was seen. GPx activity decreased until day 3 (p<0.01),
and was higher on days 0 and 1 in infants with RDS. The activities of GPx on day 3 and G6PDH
and GCL on day 1 were highest in the most preterm infants. The activity of GPx was higher on
days 0 and 1 in infants with RDS (p<0.05), and the activity of GR on day 7 was higher in those
who later developed BPD (p<0.01).
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DISCUSSION
1.   Methodological aspects
In the pharmacokinetic study (I) the study population was small and thus rather heterogeneous,
with many different clinical problems needing a variety of intensive care interventions. However,
the dosage in the RCT (II), chosen according to the results from the pharmacokinetic study
resulted in plasma levels of NAC that were well within the range for which we aimed. While it
would have been of interest to study the urinary excretion of NAC, collecting urinary samples
from tiny preterm infants with vulnerable skin is stressful for the patient and usually results in
incomplete daily volumes. 
As the amount of blood that can be drawn from ELBWI for research purposes is limited, we were
not able to collect blood samples repeatedly. For ethical reasons, no blood samples were obtained
during the early postnatal phase before informed consent was received from the parents. In the
study of markers of oxidative stress (III), samples from earlier time-points would have been of
value in evaluating the role of 8-isoprostane in the pathophysiology of different complications of
prematurity. The present results only show that 8-isoprostane is increased in infants acquiring
BPD or PVL, but no conclusions can be made about whether it contributes to disease development
or is merely a consequence of the developing disease. Nevertheless, the results do suggest that
oxidative stress plays a role in the pathogenesis of these complications.
The small amount of plasma available also limited the sample purification procedure in the 8-
isoprostane study (III). Unpurified plasma samples can contain interfering agents. Sample
purification with resins is possible, but problems exist with quantitative purification when samples
are as small as in this case. This is because binding to resins is never 100% complete or specific.
Unspecific or incomplete binding would have had a large effect on our tiny samples. There are
other more specific methods to determine isoprostane concentration, such as GC/MS. This was,
however, not available to us, and hence, we assumed that although the EIA method used would
create a large spread of values, no systematic errors would exist between groups.
We did not carry out a pilot study prior to the RCT (II), but performed an interim safety analysis
after the first 40 infants were enrolled at the Hospital for Children and Adolescents, Helsinki
University Central Hospital. A pilot study with a small population size would not necessarily have
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revealed the efficacy of the drug of interest, and in any case, the results would need to be
confirmed in a larger trial. A pilot study could, however, have shown serious side-effects. The
pharmacokinetic study (I) showed no side-effects or adverse events ascribable to NAC, which is a
well-known drug that has been used in adults and in children for decades. We enrolled 194 infants
in the NAC group and 197 infants in the placebo group, which is beyond the sample size needed
to show a 33% reduction in the incidence of BPD or death. The randomization was stratified to
each centre in blocks of 10 patients to minimize the influence of changing treatment routines at the
centres during the study period. The monitoring and safety committee monitored adverse events in
the study; any serious adverse events that occurred during the first 14 days were reported directly
to Draco Läkemedel AB (II). To show any decrease in the other complications of prematurity,
with a much lower incidence, a considerably larger trial would be required.
In the study of oxidative markers, only samples from infants enrolled at one centre, the Hospital
for Children and Adolescents, Helsinki, were included to ensure adequate and identical handling
of all samples.
The determination of intracellular glutathione concentration in various tissues, especially in the
lung, would have been of interest when studying the role of glutathione status in the development
of BPD. Erythrocytes do not necessarily represent the situation of the entire organism or of a
specific organ, but lung and other tissue biopsies of preterm infants are impossible to obtain (IV). 
We did not measure reduced glutathione (GSH) and oxidized glutathione (GSSG) separately.
Since our tests have shown that reliable GSH measurement requires immediate and special sample
handling, we decided to measure total glutathione, thus avoiding flawed results caused by
oxidation of GSH to GSSG after sample collection. 
2.   NAC in preventing complications of prematurity
A 6-day infusion of NAC during the first week of life did not prevent death or BPD at the age of
36 gestational weeks in ELBWI. The reason for the lack of efficacy may be incorrect dosage,
timing or rationale for the study. The dosage was based on our pharmacokinetic studies, which
showed that the elimination half-life of NAC is much longer in preterm infants than in adults
(Prescott et al. 1989). It took 2-3 days until a steady-state concentration was reached, except in one
infant, in whom the concentration kept rising during the 6-day period. This can be explained by
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either a saturation of NAC metabolism or a very long half-life of NAC. Unlike the CL and Vd, the
t1/2 did not correlate with weight or gestational age. We aimed at a plasma NAC level of 100-300
µmol/l, based on a study in adults with myocardial infarction in which NAC treatment at a mean
plasma concentration of 172 µmol/l was shown to limit oxidative stress when measured by the
GSH/GSSG ratio (Arstall et al. 1995). Our own unpublished studies on human bronchial epithelial
cells exposed to oxidants have also shown a beneficial effect of NAC at concentrations between
100 and 500 µmol/l. In studies of NAC treatment in paracetamol poisoning, plasma concentrations
of NAC as high as 1.8-5.5.mM in the beginning of the infusion with a loading-dose and a steady-
state concentration of 200 µmol/l at the end of the infusion have been reported (Prescott et al.
1989). The mean plasma NAC concentration in the RCT (II) was 170 µmol/l on day 3 and 172
µmol/l on day 7, which are well within the range in which NAC has been shown to have beneficial
effects. Although NAC has proven to be a relatively safe drug, some adverse effects have been
reported (Mant et al. 1984). In addition, high-dose NAC was demonstrated to increase mortality in
rats exposed to endotoxin-related oxidative stress, whereas low-dose NAC had beneficial effects
(Sprong et al. 1998). Therefore, aiming at much higher plasma concentrations did not seem
reasonable.
We started the NAC infusion at a mean age of 24 h. Evidence of oxidative stress in preterm
infants has been shown already during the first day of life (Nycyk et al. 1998, Ogihara et al. 1999),
and evidence of inflammation in the amniotic fluid and cord plasma even earlier (Yoon et al.
1999). It may be speculated that the commencement of NAC treatment was too late to efficiently
inhibit injurious oxidation and the development of BPD. However, an earlier start could have
resulted in the enrolment of several infants with less risk factors for developing BPD. Even if the
insults leading to the development of BPD start before birth, postnatal events are also important.
Therefore, some positive effect of NAC is expected despite treatment starting at the age of 24 h.
NAC may not work in preterm infants as expected or it may confer no protection against BPD
development. One reason for the lack of effect might be poor deacetylation of NAC in preterm
infants. Although adult human liver and endothelial cells are able to deacetylate NAC (Sjödin et
al. 1989, Cotgreave et al. 1991, Uttamsingh et al. 1998), no studies have been done on deacetylase
activity in preterm infants. The long half-life of NAC might be the result of immature hepatic
deacetylation activity. In a study of intravenous amino acid solutions for preterm infants where
NAC was used at a low dose as a source of cysteine in a commercially available amino acid
solution (Aminovenös-N-päd 10%, Fresenius AG, Bad Homburg, Germany), more than half of the
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NAC was excreted unchanged in urine (van Goudoever et al. 1994). Even if NAC was not
deacetylated, it can, through its thiol group, replace cysteine in mixed disulphides in plasma, thus
increasing the availability of free cysteine for cellular uptake. However, no reliable data exist on
the proportion of free vs. bound cysteine in the plasma of preterm infants. NAC could also work
as a direct scavenger in plasma (Aruoma et al. 1989). In animal studies of lung injury where NAC
had a positive effect, no increase in intracellular GSH concentration was observed (Langley and
Kelly 1993, Davreux et al. 1997).
The plasma glutathione and cysteine concentrations did not increase during NAC infusion, in fact,
they were lower in infants who received NAC. Plasma glutathione concentration is not directly
related to intracellular glutathione concentration. The liver can produce glutathione for other
organs, and hepatocytic secretion of glutathione increases plasma glutathione concentration, but
oxidative stress increases glutathione oxidation in cells, which then secrete GSSG to plasma. The
lack of correlation between plasma NAC and cysteine has been observed earlier in adults and
neonates (Magnusson et al. 1989, van Goudoever et al. 1994). However, the combined plasma
concentration of thiols was much higher in infants receiving NAC. High levels of cysteine are
toxic (Puka Sundvall et al. 1995), thus, the plasma cysteine level is regulated. Cysteine is taken up
by cells as needed, and excessive NAC or cysteine is excreted in urine. NAC has been shown to
increase GSH synthesis only when the need for GSH is increased, as in paracetamol poisoning
(Burgunder et al. 1989). Therefore, the failure of NAC to increase plasma glutathione or cysteine
concentration has been speculated to be due to lack of deficiency of these substances (Welty
2003); the supplementation of amino acids in the RCT was started during the first 2 days.
Biochemical differences between plasma and intracellular thiols should also be considered. The
plasma levels of glutathione in our study are much higher than those reported by others (Smith et
al. 1993, Jain et al. 1995). However, comparison of glutathione and cysteine levels between
different studies is difficult because of the different analytical methods used. We measured total
glutathione after reduction and release from disulphides. Our study on thiol metabolism during the
first week of life (IV) showed that an initial decrease occurs in plasma cysteine in infants given
similar supplementation as in our RCT, and that a correlation exists between plasma cysteine
levels and gestational age, consistent with findings by others (Arnold et al. 1989, van Goudoever
et al. 1995, Viña et al. 1995). We also showed a decrease in erythrocyte glutathione concentration
during the first week of life. Erythrocyte glutathione concentration was significantly lower on day
1 in infants who later died or developed BPD (IV), supporting the theory that these infants have a
relative glutathione deficiency. Our aim was to increase the intracellular glutathione concentration,
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but as shown in the thiol study (IV), plasma glutathione concentration does not reflect the
glutathione status in cells, at least not in erythrocytes. Unfortunately, the effect of NAC on
intracellular glutathione levels could not be studied in the RCT. 
We also did not show any effect of NAC on the other complications of prematurity. Although the
incidence of PVL was 39% higher in the placebo group, the difference was not statistically
significant. Because the incidences of PVL, ROP, IVH and NEC are quite low, the sample size
must to be much larger to show a significant decrease, even a clinically significant decrease. With
more sophisticated magnetic resonance imaging methods, the degree of white matter injury could
be assessed (Inder et al. 2003); however, these methods were not applied here. Thus, the effect of
NAC on brain damage in this trial can only be assessed in an extended follow-up using a well-
designed and standardized neuropsychological test.
Reliable indicators of oxidative stress would have been valuable prior to the RCT. The effect of
NAC could thus have been assessed on them in an extended pharmacokinetic study or a pilot
study. As no golden standard indicators were available, we chose to study the indicators
proposed in the RCT infants.
To our knowledge, this was the first randomized controlled trial on intravenous NAC in the
treatment of premature infants. Although we failed to show any beneficial effects of NAC in
preventing BPD, the study yields important information in determining specific mechanisms for
the development of BPD and other oxidative stress-related complications in preterm infants.
Whether prenatal treatment has a beneficial effect remains to be tested.
3.   Markers of oxidative stress
We demonstrated an association between plasma free 8-isoprostane and the development of BPD
and PVL. This finding is in accordance with previous studies that have shown evidence of the role
of oxidative stress in the development of complications of prematurity (Pitkänen and Hallman
1998, Saugstad 1998). No other studies on 8-isoprostane in preterm infants acquiring BPD have
thus been reported.
 
8-isoprostane is a potent vasoconstrictor of pulmonary vascular and airway smooth muscle,
evoking strong biological responses in many cell types of the lung (Janssen 2001). Isoprostanes
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have been speculated to play a role in pulmonary pathophysiology. However, based on our results,
it remains uncertain whether 8-isoprostane is implicated in the pathogenesis of BPD or PVL, or
whether it is merely a marker of oxidative stress. Although elevated 8-isoprostane concentrations
have been found in tracheal aspirates on term infants with severe pulmonary disease (Goil et al.
1998), in bronchoalveolar lavage fluid of adults with interstitial lung diseases (Montuschi et al.
1998), in plasma in cystic fibrosis (Collins et al. 1999), and in exhaled breath condensate in adult
respiratory distress syndrome (ARDS) (Carpenter et al. 1998), no causative effect of 8-isoprostane
has been shown. We chose to study plasma samples because we were also interested in
extrapulmonary complications of oxidative stress. According to our results, 8-isoprostane may
potentially serve as a marker in assessing risk for BPD in ELBWI. To clarify the role of 8-
isoprostane in the pathogenesis of BPD, samples from earlier time-points, both from plasma and
tracheal aspirates, should be examined.
Plasma 8-isoprostane can be measured either in free form, as we did here, or after hydrolysis from
phospholipids, but these do not necessarily reflect the same events. In one study, total 8-
isoprostane concentration was increased in both pre-eclamptic and healthy pregnant women as
compared with non-pregnant women. Furthermore, free, but not total, plasma 8-isoprostane was
increased just before delivery in pre-eclamptic women, compared with 8-isoprostane levels in
pregnant women without pre-eclampsia (Barden et al. 1996). This suggests that free 8-isoprostane
may contribute to the pathogenesis of pre-eclampsia through direct or indirect vasoconstrictor
actions.
Both 8-isoprostane and ascorbyl radical levels were increased in infants who later developed PVL.
These results are in accordance with a previous study in which increased levels of 8-isoprostanes
and MDA, another marker of lipid peroxidation, were found in cerebrospinal fluid in VLBWI with
white matter injury (Inder et al. 2002b). Increased amounts of ascorbyl radical and 8-isoprostane
in cerebrospinal fluid have also been reported in children with traumatic brain injury (Bayir et al.
2002). Increased levels of ascorbyl radicals in brain homogenate were found during early
reoxygenation in a rat model of hypoxic-ischaemic brain injury (Bågenholm et al. 1997). This
may, however, reflect more the quenching of the radical cascade by ascorbic acid than its role in
the pathogenesis of white matter injury. Our results support the hypothesis that ROS are involved
in the oligodendroglial cell death resulting in PVL (Volpe 2003). However, the low incidence of
PVL and the large distribution of values in our study warrant cautious conclusions regarding the
usefulness of these markers in evaluating risk for PVL in ELBWI.
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NAC treatment had no influence on either plasma free 8-isoprostane or plasma ascorbyl radical
levels. The reason for this is most likely the same as for the failure of NAC to prevent BPD or
death, as discussed earlier. Although we could not show any beneficial effects on outcome at the
age of 36 gestational weeks, determining a positive effect on oxidative markers would have been
useful.
4.   Thiol metabolism and erythrocyte glutathione cycle enzymes
Preterm infants have previously been demonstrated to have a relative deficiency of glutathione
(Jain et al. 1995, Viña et al. 1995), due to developmentally deficient liver cystathionase activity
(Sturman et al. 1970). In our study, the plasma glutathione concentration increased from the first
hours of life to the age of one day, then decreasing towards the end of the first week. The
erythrocyte glutathione level decreased during the first week of life. However, we were unable to
show any correlation between plasma glutathione concentration and gestational age, contrary to a
previous study (Jain et al. 1995). An initial decrease in erythrocyte glutathione concentration in
preterm infants has been described earlier, and a similar decrease was seen in term infants,
followed by a slight increase at the age of 3 days, but the erythrocyte glutathione levels in preterm
infants were not preserved (Jean-Baptiste and Rudolph 2003). Failure to maintain intracellular
glutathione levels might render preterm infants vulnerable to oxidative damage.
Despite early supplementation with amino acids, the plasma cysteine concentration initially
decreased and then increased, consistent with findings that preterm infants have a relative cysteine
deficiency (Sturman et al. 1970, van Goudoever et al. 1995). In addition, a positive correlation
was present between plasma cysteine concentration and gestational age in infants appropriate for
gestational age, as also shown by others (Viña et al. 1995). Infants with RDS had a lower plasma
glutathione concentration during the early hours of life, but infants later acquiring BPD had a
higher plasma glutathione concentration on day 1 of life. Erythrocyte cysteine and glutathione
concentrations on day 1 were also lower in infants who subsequently developed BPD. These
findings may be explained by the increased consumption of glutathione in early life, when the
infant is exposed to ROS. Glutathione synthesis first increases and then an increased amount of
glutathione is transported in the plasma to different organs such as the lung. However, when the
supply of cysteine is insufficient, the intracellular level of glutathione decreases.
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The relationship between erythrocyte antioxidant capacity and the complications of prematurity is
important in neonatology. Erythrocytes can scavenge free oxygen species and protect other tissues
from oxidative injury (Heffner and Repine 1989). The vulnerability of erythrocytes to oxidative
stress, their antioxidant enzyme activities and thiol concentration have previously been studied by
others, but only a few studies have focused on the behaviour of enzyme activities and thiol
concentrations during the neonatal period in preterm infants (Moison et al. 1997b, van Zoeren-
Grobben et al. 1997, Neefjes et al. 1999). We showed no increase in GPx activity during the first
week of life, in contrast to a study in term infants (Bracci et al. 1988). This finding might be
relevant for the ability of preterm infants to respond to oxidative challenge. The GCL and GR
activities did not change, but the activities of G6PDH and GSTs decreased, as other studies have
also reported (Bracci et al. 1988, Neefjes et al. 1999). However, further research is needed to
elucidate the role of glutathione redox cycle in preterm infants. Some infants, especially in the
ELBWI group, received red cell and plasma transfusions during the study period, and this may
have had some effect on our results.
5.   Future prospects
Although we failed to show any beneficial effects of NAC treatment on the development of BPD,
this does not rule out the possibility that some other precursor of cysteine, or glutathione mimetic,
would be effective. While oxidative stress is implicated, other factors may also contribute to the
pathogenesis of BPD and other complications of prematurity. The balance between different
antioxidant defences may be more important than the capacity of any individual mechanism.
Future studies on the pathophysiology of neonatal complications will hopefully elucidate the role
of thiols in these processes. This knowledge, combined with additional data on thiol metabolism,
such as deacetylation of NAC in preterm infants, will indicate which thiols should be further
investigated in a RCT.
 In addition, to better understand the role of oxidative stress in the pathogenesis of different
complications of prematurity, reliable markers of oxidative stress should be developed and
evaluated. With proper measures, following the effect of treatments aimed at prevention of these
complications, and identifying high-risk infants would be possible. Based on our findings, 8-
isoprostane may be a valuable marker of oxidative stress in preterm infants. Its role in disease
development in newborn infants warrants further study.
Conclusions
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CONCLUSIONS
The main conclusions of our studies aiming at the prevention of oxidative stress-related
complications of prematurity with NAC are as follows:
Elevated plasma free 8-isoprostane is associated with BPD and PVL. An association also
exists between elevated plasma ascorbyl radical signal in early life and PVL. The data suggest
that plasma 8-isoprostane could serve as a marker in assessing the risk for BPD development
in ELBWI.
NAC is eliminated slowly in preterm infants, with a mean half-life of 11 h, which is
noticeably longer than in adults. Clearance and volume of distribution, but not elimination
half-life, correlate with birth weight and gestational age.
A 6-day course of intravenous NAC, starting at the age of 24 h, at the dosage used (16-32
mg/kg/d), did not prevent death or BPD in ELBWI. Nor did it have an effect on the incidence
of ROP, IVH or NEC. A slight non-significant difference was, however, observed in the
incidence of PVL. Whether the treatment had any beneficial effect on brain injury remains to
be investigated with more sensitive measures in a follow-up study.
 
In VLBWI, the plasma glutathione increases and the plasma cysteine decreases in the
beginning of the first week of life. The most preterm infants have the lowest cysteine levels in
proportion to the degree of maturity. In erythrocytes, the intracellular cysteine and glutathione
levels correlate positively. Erythrocyte thiol concentration could serve as a marker in studies
where attempts are made to strengthen the antioxidant capacity by increasing intracellular
glutathione levels by cysteine precursors. 
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